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Highlights 
 Combining oxaliplatin regimens with certain traditional medicine interventions in 
CRC appears to reduce CIN incidence. 
 For the five plants associated with the greatest CIN reductions, experimental studies 
have reported effects on myelosuppression and/or immune response. 
 These plants and their constituents warrant further investigation as sources of 
potential interventions for CIN. 
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Abstract 
This review assessed the effects on chemotherapy induced neutropenia (CIN) of combining 
oxaliplatin regimens with traditional plant-based medicines (TMs) in the management of 
colorectal cancer (CRC). 32 RCTs (2,224 participants) were included. Meta-analysis showed 
reduced incidence of grade 3/4 CIN (RR 0.45[0.31, 0.65], I²=0%). No studies reported serious 
adverse events or reduction in tumour response rates associated with concurrent use of 
oxaliplatin and TM. Due to small sample sizes and risk of bias, these results should be 
interpreted with caution. Analyses of sub-groups of studies that used similar TM interventions 
assessed the relative contributions of individual plant-based ingredients to the results. 
Astragalus, Codonopsis, Atractylodes, Poria and Coix, in various combinations were 
consistently associated with reduced CIN incidence when administered orally. Experimental 
studies of these plants have reported reduced myelosuppression and/or enhanced immune 
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response. Further studies of these plants may lead to the development of interventions to 
supplement conventional CIN treatment. 
Abbreviations 
5-FU: 5-fluorouracil 
AEs: adverse events  
ANC: absolute neutrophil count 
APS: Astragalus polysaccharides 
BMSC: bone marrow stromal cells 
CFU-F: colony-forming unit-fibroblast 
CIN: chemotherapy induced neutropenia 
CNKI: China Academic Journals 
CQVIP: Chinese Science and Technology Journals  
CRC: colorectal cancer 
FN: febrile neutropenia  
FOLFOX: 5-fluorouracil (5-FU) plus leucovorin (LV) combined with oxaliplatin 
G-CSF: granulocyte colony-stimulating factor  
GM-CSF: Granulocyte-macrophage colony-stimulating factor 
KPS: Karnofsky Performance Status 
LV: leucovorin 
MD: mean difference 
NCI-CTC: National Cancer Institute Common Toxicity Criteria 
RCT: randomized controlled trial 
RE: random effect model 
RR: risk ratio 
TMs: traditional medicines  
WHO: World Health Organisation 
XELOX: capecitabine plus oxaliplatin 
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Introduction 
Colorectal cancer (CRC) is the second most common cancer in women and the third most 
common in men. In 2012 the World Health Organisation reported there were 1.4 million new 
cases and 694,000 deaths worldwide from CRC. This was an increase in both incidence rate 
and mortality compared with the 2010 study [1]. Oxaliplatin is a third generation platinum 
drug which inhibits DNA repair and replication, resulting in cell death [2]. In CRC treatment, 
standard chemotherapies in both adjuvant and palliative settings use oxaliplatin combined 
with 5-Fluorouracil (5-FU) or Leucovorin (LV)(referred to as FOLFOX), or oxaliplatin with 
oral capecitabine which converts to 5-FU in the body (referred to as XELOX)[3,4]. 
 
Chemotherapy induced neutropenia (CIN) is a decline in absolute neutrophil count (ANC) as 
a result of myelosuppression induced by systematic chemotherapy [5]. Neutropenia can lead 
to life-threatening infections so it is common practice to decrease dose intensity or cut short 
treatment cycles when serious neutropenia is evident but this will directly affect the 
effectiveness of the chemotherapy [6]. CIN severity is classified into four grades based on 
decline in ANC [7]. Febrile neutropenia (FN) is a serious condition that combines elevated 
body temperature, sepsis and severe neutropenia [7,8]. Risk factors for CIN include age, 
performance status, nutritional status, chemotherapy dose intensity, and low baseline blood 
cell counts [9]. 
 
CIN is one of the most common adverse reactions in CRC treatment using oxaliplatin 
regimens [10]. In CRC clinical trials the incidence of grade 3/4 CIN was found to vary from 
37% to 56% in different populations [11] and CIN incidence has been found to be higher in 
regimens that combine oxaliplatin with 5-FU compared to single 5-FU regimens [12,13]. This 
may be associated with oxaliplatin reducing 5-FU plasma clearance by inhibiting 5-FU 
catabolism [14]. 
 
Granulocyte colony-stimulating factor (G-CSF) initiates the proliferation of granulocyte 
precursor cells and their differentiation into mature granulocytes in bone marrow. Clinical 
trials have found that recombinant G-CSF significantly reduced the incidence of grade 3/4 
CIN and accelerated cancer patients’ recovery from CIN after chemotherapy, thereby making 
higher-intensity treatment regimens possible [15-18]. In the past, G-CSF treatment was 
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expensive [19] but the advent of biosimilars has made G-CSF support for CIN/FN 
prophylaxis more cost-effective [20]. 
 
With the aim of reducing adverse events (AEs) and improving clinical outcomes, some 
clinicians combine chemotherapy with traditional plant-based medicines (TMs) [21]. Several 
reviews have reported that chemotherapy combined with TMs could reduce AEs including 
CIN in various cancers [22-24]. In advanced CRC, a meta-analysis of RCT results showed 
FOLFOX4 combined with TMs reduced grade 3/4 CIN by 8.7% compared to FOLFOX4 
alone [25]. Some plants frequently used in the TMs, including Astragalus membranaceus 
(Fisch.) Bge., Panax ginseng C.A. Meyer, Atractylodes macrocephala Koidz., Poria cocos 
(Schw) Wolf and Coix lachry-jojobi L., have been reported to produce immunomodulatory 
effects in experimental studies [26-29]. These effects may, at least partially, account for the 
reported clinical benefits but it remains unclear which, if any, of these TMs could reduce the 
incidence of CIN when combined with chemotherapy for CRC. 
 
In this review, we aimed to: 1. assess the clinical trial literature on the effects of TMs on CIN 
associated with the use of oxaliplatin regimens for CRC; 2. identify which TMs, or 
combinations of TMs, were associated with CIN alleviation when used in combination with 
oxaliplatin regimens in the clinical trials; and 3. identify directions for further clinical and 
experimental research. 
We conducted a meta-analysis of randomized controlled trials (RCTs) of TMs combined with 
oxaliplatin regimens for CRC which reported data on CIN incidence. Then we used sensitivity 
analyses of sub-groups of studies that used the same or similar TM interventions to assess the 
potential contributions of individual plant-based ingredients to the meta-analysis results. For 
the plants that appeared most likely to be contributing to reduced CIN incidence, we reviewed 
the experimental literature to identify possible mechanisms of action. 
2. Method  
The following databases were searched: PubMed, EMBASE, Cochrane CENTRAL, CINAHL, 
Science Direct, PsycINFO, China Academic Journals (CNKI) and Chinese Science and 
Technology Journals (CQVIP). Search terms were in three groups: 1. Disease: colorectal 
cancer and related terms; 2. Intervention type: traditional medicine, herbal medicine, 
complementary medicine, and related terms; and 3. Study type: controlled trial, randomized 
and related terms. Hand-searches were conducted of reference lists in review articles and 
additional Chinese language journals (see Supp 1 for terms used for PubMed and list of 
journal that were hand searched). There were no restrictions on language or publication year. 
Participants were adults over 18 years who had been diagnosed with CRC based on pathology 
tests and had undergone chemotherapy using an oxaliplatin regimen. No other restriction was 
placed on the age, gender or performance status of participants. Included studies were RCTs 
of an oxaliplatin regimen combined with a concurrent TM intervention in the test group 
compared with the same oxaliplatin regimen in the control group. The TM interventions 
contained natural products and could be administered systemically by any administration 
route. Studies that employed G-CSF were analysed separately. All RCTs reported on CIN 
(neutropenia or leucopenia) as an outcome measure. Studies that only reported on 
myelosuppression, or reported data in a form unsuitable for analysis were excluded. 
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Records were kept of the numbers of studies at each stage in the search and selection process. 
These were summarised in a flowchart according to the PRISMA guidelines. Two reviewers 
(M.Chen & I.Zhou) independently extracted data. Risk of Bias (RoB) was assessed by MC 
and IZ with mediation by A. Zhang. RoB included selection bias, performance bias, detection 
bias, attrition bias, and reporting bias. For each study, each domain was judged ‘low risk’, 
‘high risk’ or ‘not reported’ when the information was not mentioned or incomplete. 
Meta-analysis was conducted using Review Manager (RevMan) 5.1 as Risk Ratio (RR) or 
Mean Difference (MD) with 95% confidence intervals (95% CI) using random effects models. 
Incidence rates were expressed as the percentage of the number of participants with CIN in 
the group divided by the total number of the participants in the group. Studies with zero 
events were included to avoid overestimation of effect [31]. Proportion of heterogeneity was 
measured using I². If I² was over 50%, indicating important heterogeneity, sensitivity 
analyses were performed to explore the sources of heterogeneity. Publication bias was 
assessed using a funnel plot [32] Effect of number of cycles of chemotherapy on CIN 
incidence was calculated using mean incidence rate (%) with the standard error (SE).  
2.1 Subgroup analyses 
Subgroup analyses were planned for route of TM administration – intravenous (IV) or oral 
and studies employing G-CSF. Data analysis for CIN was stratified by: FN, CIN grade 4, CIN 
grade 3, CIN grade 3/4, CIN grade 1/2, and CIN all grades. To determine if the addition of the 
TMs affected the effectiveness of the chemotherapy, meta-analysis of tumour response rate 
(tRR) was conducted for the studies in the groups for CIN grade 3/4 and all grades.  
2.2 Sensitivity analyses of orally administered TM interventions 
For studies of multi-ingredient orally administered TM interventions further sensitivity 
analyses were planned based on the composition of the TM interventions. We reasoned that if 
a particular ingredient was effective (or ineffective) in alleviating neutropenia, this would be 
reflected in the pooled RR outcomes of the studies that employed this ingredient in the 
intervention. Therefore, by investigating the pooled RR of studies that used the same 
ingredient, or same combination of ingredients, we could identify those that showed potential 
for further research into interventions for neutropenia alleviation.  
The following approach was used. Firstly, TM interventions which had plant-based 
ingredients in common were identified. Then, sensitivity analyses were conducted for groups 
of TM interventions that contained the same ingredients to determine which plants, and 
combinations of plants, produced greater or lesser changes in RR values for CIN all grades. 
The following multi-level procedure was used:  
Level 1. Single plants present in two or more TM interventions were identified and the pooled 
RR was calculated for each subgroup of studies that contained the same plant as an ingredient. 
The pooled RRs (95%CI and I2) were listed in ascending order and any significant results 
were noted. Plants that had significant results that did not show important heterogeneity (I2 
not greater than 30%) were considered for higher level combinations. 
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Level 2. Plants that had significant results at level 1 were paired with other plants that showed 
significant results at level 1 to produce a matrix of results. The RRs of the pairs were listed in 
ascending order and any significant results were noted. 
Level 3 and above. Pairs of plants present at level 2 that had significant results were 
combined with other plants from level 1 to produce combinations of 3, 4 and more plants as 
the data set allowed. The pooled RRs of these combinations were listed in ascending order 
and any significant results were noted.  
This procedure produces groups of studies that have, one, two and more plants as common 
ingredients in the TM interventions.  
Only actual combinations of plants that were present in the oral TM interventions were 
included. For example, although plant 1 could be paired with plant 2 in the data matrix, all the 
TM interventions that contained plant 1 + plant 2 may also have included plant 3. In such 
cases, the RR of TM interventions in this group of studies actually reflects the combination of 
all 3 plants (as well as any other plants present), so there is no independent contribution to the 
RR from plant 1 + plant 2 at Level 2. Therefore this pair was excluded from Level 2. Instead, 
the group, plant 1 + plant 2 + plant 3, was included in the RR matrix at Level 3. 
2.3. Selection of plants for further research 
To select plants for further research, the following selection criteria were used: 1. the RR of 
the group of two or more studies that contained the same plant(s) in the TM interventions was 
significantly decreased relative to controls; 2. the RR was equal or lesser than the total pooled 
RR for the multi-ingredient oral TM interventions; 3. lack of important heterogeneity (I2 not 
greater than 30%); and 4:the plant appeared at multiple levels of combination with 
consistently significant RR results. When combinations of plants produced RRs that were 
lower than those of the plants individually, these were identified as possible examples of a 
synergistic effect. 
3. Results 
The searches located 2,648 potentially relevant citations and searches of reference lists and 
print journals located an additional 54 potential studies. Following screening, 280 full-text 
studies were evaluated which included 88 studies of TMs combined with chemotherapy for 
CRC, 79 of which employed oxaliplatin regimens. Of these, 39 did not report on CIN, 
neutropenia or myelosupression, sixreported on mylosuppression or hematologic events only 
and two reported data that were not suitable for meta-analysis. Finally, 32 studies (2,224 
participants) that combined an oxaliplatin regimen with a TM versus the same oxaliplatin 
regimen and reported outcome data for CIN were included (Fig. 1). Of these, two studies 
Deng and Shen (2010)[33] and Fang and Li (2008) [34] used G-CSF and two reported 
neutrophil count as mean difference [35,36], so these studies were analysed separately. 
 
All studies were published from 2005 to 2013. 31 studies were conducted in China and one in 
Japan [37]. The studies reported all participants were diagnosed as CRC based on pathology 
tests, and had adequate liver and kidney function and peripheral blood count or no 
contraindication to chemotherapy pre-study. 26 studies specified life expectancy of three 
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months or longer and 17 studies specified no use of chemotherapy for at least one month prior 
to study commencement (Table 1, TableSupp1, Table Supp 2).  
 
Oxaliplatin regimens included FOLFOX in 30 studies and XELOX in two studies [33,38]. 
The TMs and chemotherapy were used concurrently. Orally administered TMs were used in 
24 studies and 8 studies employed commercially available TM injections. Chinese studies 
were carried out in the authors’ hospital and participants were in-patients. Participant 
characteristics, interventions, doses and schedules are recorded in Table 1. 
3.1. Methodological assessment 
All studies were described as RCTs. 13 (40.6 %) reported a proper method of random 
sequence generation and were judged as ‘low’ risk of bias (Table Supp 3). The other studies 
did not report the method of sequence generation. No studies reported on how participants 
were screened. The single study that used external trial management was judged ‘low risk’ for 
allocation concealment and blinding of participants and personnel [37]. The other studies did 
not report on allocation concealment. When there was no identical placebo, studies were 
judged ‘high risk’ for blinding of participants or personnel. Details of outcome assessment for 
CIN were not reported but this is an objective outcome which is measured by laboratory 
pathologists in a hospital setting so results were unlikely to have been influenced by lack of 
blinding. Two studies reported the numbers of participants who dropped out during the trial or 
were lost to follow-up [39,40] but no reasons were given and these missing data were not 
treated as ‘intent to treat’, so these were judged as ‘high risk’ of attrition bias. Studies that had 
the same numbers of participants at inception as in the outcome reports were judged as ‘low 
risk’ of attrition bias. One study had a locatable protocol and was judged as ‘low risk’ of 
reporting bias. When there was no protocol the judgement was ‘high risk’. The funnel plots 
for the 32 studies that reported CIN incidence showed asymmetry, so it is likely that were 
some small studies that did not report CIN data that was non-significant (Figs. Supp 1a & 1b). 
3.2. Meta-analysis of change in CIN 
All studies used the WHO system or National Cancer Institute Common Toxicity Criteria 
(NCI-CTC) for grading acute and sub-acute toxicity which divides CIN into 4 grades [41,42]. 
Data were reported as RR in 30 studies. Meta-analysis was conducted for FN, CIN grade 4, 
grade 3, grade 3/4, grade 1/2and all grades combined. Data reported as MD for neutrophil 
counts (2 studies) were analysed separately. When RR is less than +1 or MD is less than zero 
it favors the test group. Only one study reported FN data (see oral administration group). 
 
The overall results showed the test groups significantly reduced CIN compared to control 
groups for grade 4, grade 3, grade 3/4, grade 1/2 and all grades with no statistical 
heterogeneity (I2 =0%)(Table 2, Fig Supp 2a). Results are also reported for the following sub-
groups: 1. injection group without G-CSF (7 studies); 2. oral administration group without G-
CSF (21 studies); 3. studies that used G-CSF (2 studies); and 4. neutrophil count group (2 
studies). 
 
3.2.11. Injection group (no G-CSF) 
Seven studies tested five different injection products, three of which were tested in two 
studies each (Table 1). There was no difference between groups in the single study that 
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reported grade 4 CIN or in the four studies that reported grade 3. There were significant 
differences in grade 3/4, grade 1/2, and all grades with no heterogeneity. Incidence rates for 
grade 3/4 were 4.5% in the test groups versus 11.1% in the controls (Table 2, Fig Supp 2a). 
3.2.2. Oral administration group (no G-CSF) 
In 21 studies, TMs were administered orally as decoctions, capsules or tablets. In the four 
studies that reported grade 4, there was no significant difference between groups. Significant 
differences were found for grade 3, grade 3/4, grade 1/2, and all grades with no heterogeneity. 
Incidence rates for grade 3/4 were 4.6% in the test groups versus 11.8% in the controls (Table 
2, Fig Supp 2a). The single study that reported FN (n=89) [37] found no significant difference 
between groups. 
3.2.3. G-CSF group 
One study used an injection [34] and one used oral TM [33]. For the pooled data there was no 
significant difference between groups in grade 3/4andall grades neutropenia. No data were 
available on FN (Table 2, Fig Supp 2a). 
3.2.4. Neutrophil count 
In the two studies that presented data as mean neutrophil count [35,36] there was a significant 
difference in favour of the test groups MD 1.62 [0.93, 2.32] I2=66%(Table 2, Fig Supp 2b). 
 
 
3.3. Effect of number of cycles of chemotherapy on CIN incidence 
Grade 3/4 CIN incidence was stratified by number of cycles of chemotherapy (2, 3, 4, 6, 8+) 
for the oxaliplatin control groups and the test groups (Table Supp 3). In the control groups, 
the mean grade 3/4 CIN incidence was higher at 2 cycles (12.30%) than at 3 cycles (6.92%), 
but then the incidence increased with increasing number cycles to 19.00% for 8 or more 
cycles (Fig 2). There were significant reductions in grade 3/4 CIN incidence in the test groups 
for two cycles RR 0.37 [0.17, 0.80] and four cycles RR 0.26 [0.10, 0.66] with a marginal 
difference at 6 cycles RR 0.36 [0.13, 1.02], p=0.05.There were no significant differences at 3 
and 8 cycles or more. It was not feasible to calculate accumulated oxaliplatin and 5-FU dose 
due to variation in data reporting. 
3.4.Meta-analysis of tumour response rate (tRR) 
To test whether the reduction of CIN was associated with reduction of the cytotoxicity of the 
chemotherapeutic agents, we pooled results the studies that also reported tRR. Data were 
available for 6 studies in the injection group, 17 studies in the oral group, one in the G-CSF 
group and two in the neutrophil count group. The results showed there were no significant 
reductions in tRR in the pooled data (Table 2, Fig Supp 2c). 
3.5.Effects of individual plant-based ingredients in orally administered TMs 
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The multi-ingredient TMs differed in name but their main ingredients were similar. The 
effects on reduction of CIN of the plant-based ingredients used in multiple studies are 
reported below at the level of the single plant, pair of plants, and groups of 3 up to 10 plants. 
It was not feasible to use this procedure for studies of injection products. 
All plant-based ingredients (n=85) in the oral TMs were recorded in a spread-sheet. The 
number of ingredients per intervention averaged 10 and ranged from 1 to 23. Thirty six plants 
were used in two or more interventions. The RR (CIN all grades) of the group of studies that 
included each particular plant was calculated and the RRs were ranked from low to high. The 
significant RRs were identified (n=36), and groups with moderate or higher heterogeneity (I²> 
30%) were excluded (n= 6) leaving 30 different plants in the following analyses. Since the 
aim was to select plants for further research, only significant RR results that were equal or 
lower than the total pooled RR of oral interventions (0.59 [0.53, 0.67]) are reported in the 
text. See Table 3 for all significant RR results. For each of the 30 plants, the full botanical 
name is given in the first instance together with the Chinese name in pin yin. Thereafter, the 
name is shortened to the genus only (Table 3).The most frequently used plants were: 
Atractylodes macrocephala Koidz. (bai zhu)(n=15); Poria cocos (Schw) Wolf (fu ling) 
(n=13); Coix lacryma-jobi L. (yi ren) (n=13); Astragalus membranaceus (Fisch.) Bge. (huang 
qi) (n=12), and Codonopsis pilosula (Franch.). Nannf. (dang shen) (n=10). 
 
.3.5.1. Level 1: Single plants 
Of the 30plants included at level 1, six were not always associated with another plant in the 
TM interventions (Table 3). Of these, Poria (n=13) had the lowest RR (0.50 [0.42, 0.60], 
I²=0%) followed by Panax notoginseng (Burk.) F.H. Chen (san qi) (n=4) (RR 0.51 [0.36, 
0.72], I²=0%), Codonopsis (n=10) (RR 0.54 [0.45, 0.65], I²=0%), Astragalus (n=12) (RR 0.55 
[0.47, 0.65], I²=0%), Coix (n=13) (RR 0.56 [0.48, 0.66], I²=0%), and Atractylodes (n=15) 
(RR 0.57 [0.50, 0.66], I²=0%). The remaining plants always appeared in association with at 
least one other plant. 
3.5.2. Level 2: Pairs of plants 
When the 30 plants that showed significant RR results were paired with other plants from 
level 1, thirteen pairs showed RRs that were lower than the total pool for oral TM 
interventions (Table 3). The most frequent pairs were Poria + Atractylodes (n=11) (RR 0.47 
[0.39, 0.57], I²=0%) and Astragalus + Atractylodes (n=11) (RR 0.56 [0.48, 0.67], I²=0%).The 
lowest RRs were for Poria + Coix (n=9) (RR 0.46 [0.37, 0.57], I²=0%) followed by Poria + 
Atractylodes. 
3.5.3. Level 3: Combinations of three plants 
The significant pairs from level 2 were combined with other plants from level 1. Fifteen 
different triplets showed significant RRs that were lower than the total pool (Table 3). The 
most frequent combinations were Poria + Atractylodes + Codonopsis (n=9) RR (0.50 [0.40, 
0.62], I²=0%) and Coix + Atractylodes + Astragalus (n=9) RR (0.58 [0.48, 0.69], I²=0%). The 
combination of Poria + Atractylodes + Ligusticum chuanxiong Hort. (chuanxiong) had the 
lowest RR (0.38 [0.22, 0.66], I²=0%) based on two studies. 
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3.5.4. Level 4: Combinations of four plants 
The significant combinations from level 3 were combined into groups of four, using the same 
method. Thirteen combinations were significant and lower or equal to the pool. Codonopsis + 
Astragalus + Atractylodes + Poria (n=7) RR (0.48 [0.38, 0.62], I²=0%) was the most frequent 
combination. The lowest RR was for Poria + Atractylodes + Coix + Angelica sinensis 
(Oliv.)(danggui) (n= 2) (RR 0.38[0.22, 0.64], I²=0%). 
3.5.5. Level 5: Combinations of five plants 
Eight combinations of five plants showed RRs lower than the total pool. The most common 
combination was Astragalus + Coix + Poria + Codonopsis + Atractylodes (n=6) RR (0.49 
[0.37, 0.63], I²=0%). The combination of Astragalus + Atractylodes + Poria + Coix + Smilax 
glabra (n=2) had the lowest RR (0.46[0.27, 0.80], I²=0%).  
3.5.6. Level 6: Combinations of six plants 
Nine combinations of six plants showed significant RRs lower than the total pool. The most 
common combination (n= 4) was Codonopsis + Atractylodes + Astragalus + Coix + Poria + 
Scutellaria barbata D. Don. (banzhilian) RR (0.50[0.37, 0.68], I²=0%). The combination 
Codonopsis + Astragalus + Coix + Glycyrrhiza + Atractylodes + Poria (n= 2) had the lowest 
RR (0.43[0.27, 0.68], I²=0%). 
3.5.7. Level 7: Combinations of seven or more plants 
There was one combination of seven, two combinations of eight and nine, and one 
combination of ten plants that showed RRs that were significant and lower than the total pool 
but all combinations were based on two studies only (Table 3). 
3.6. TMs with consistent results at multiple levels 
To select plants for further research we identified those that showed reduced RRs at multiple 
levels. RR results that were significant and lower than the pool total, with heterogeneity less 
than 30%,were evident at all eight levels for Atractylodes, Poria, Coix, Astragalus and 
Codonopsis when used in various combinations. Therefore, when these five plants were 
included in TM interventions the data suggested a clinical benefit for CIN based on multiple 
studies. Also, the RRs for the pools of studies that included these plants were lower than the 
total pool for oral interventions. This was also the most frequent combination of five plants. 
In the six studies (320 participants) that used this combination, the incidence of all grades 
CIN was 26.7% (47/176) compared to 56.4% (97/172) in the control groups. For 3/4 CIN, this 
combination showed a significant reduction (RR 0.41 [0.17, 0.96] I2=0, 5 studies, 295 
participants) with incidences of 4.7% (7/148) in the test groups and 12.2% (18/147) in the 
control groups. 
3.7. Potential synergistic effects of TMs 
A number of combinations of plants showed RRs that were lower than those of the plants 
singly. These included two pairs of plants: Poria+ Coix and Poria + Atractylodes; four 
triplets: Poria + Coix + Atractylodes, Poria+ Atractylodes+ Astragalus, Poria + Coix + 
Astragalus, and Poria + Atractylodes + Codonopsis; two groups of four plants: Codonopsis + 
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Astragalus + Atractylodes + Poria and Astragalus + Coix + Poria + Codonopsis + 
Atractylodes; and the group of five mentioned above: Atractylodes + Poria + Coix + 
Astragalus + Codonopsis (Table 3). 
4. Discussion 
The 32 studies included in the meta-analysis were comparable in that they all employed 
oxaliplatin regimens in the test and control groups, all participants were diagnosed with CRC, 
all studies assessed CIN incidence using the WHO criteria, all studies assess performance 
status and all required no use of chemotherapy in the month prior to commencement. With 
regard to these aspects, the included studies were similar to other studies of oxaliplatin 
regimens for CRC. One difference is these studies typically used fewer cycles of 
chemotherapy (mostly 2 to 4) than the large international studies [10,13,43] which may 
account for the relatively low CIN incidence rates. Number of cycles is an important factor in 
CIN profile. Sugihara et al 2012 [14] reported 55-88% CIN (all grades, median of 7-12 
cycles) for two Asian studies of FOLFOX 4 for CRC. The 58.9% (all grades) in the pool of 27 
studies (1840 participants) that did not employ prophylaxis with G-CSF was within this range 
(Table 2). In the case of grade 3/4 CIN, Sugihara et al 2012 reported 37-52% and Park et al 
2015 [44] reported 21.9% (median 9.7 cycles), both of which were considerably higher than 
the 11.8% (88/743) in the control groups of the pooled result for 22 studies (743 participants). 
A likely reason for this difference is seventeen of the included studies reported CIN at 4 
cycles or less of chemotherapy. For studies that employed 8 or more cycles, the CIN 
incidence for Grade 3/4 (19%) was close to the result reported by Park et al 2015 (21.9%).  
 
When the effects of number of cycles of chemotherapy on grade 3/4 CIN incidence was 
stratified by 2, 3, 4, 6, and 8+ cycles, there was a trend towards increased grade 3/4 CIN 
incidence as the number of cycles increased. In Gascon et al 2016, which included various 
cancers, there was an increase in grade 4 CIN probability with increase in cycles from one 
(7%) to six cycles (16%)[45]. The results of the present analysis support this relationship 
between CIN incidence and number of chemotherapy cycles. Some other factors that are 
known to impact in CIN/FN incidence that could not be assessed due to data availability 
included stage of cancer, treatment history and gender [8]. 
 
CIN incidence in the two studies that used G-CSF [33, 34] for two cycles was 38% (all 
grades) and 3.2% for grade 3/4 compared to the pool of studies of 2 cycles which reported 
63.1% (all grades) and 12.9% (grade 3/4). This suggests that the G-CSF was effective in 
reducing CIN incidence and there were no further reductions with the addition of the TMs.  
 
Overall, the addition of the TMs to the oxaliplatin regimens reduced all grades CIN by 24% 
(95%CI 20-28%) and grade 3/4 CIN by 6% (95%CI 3-8%). Importantly, the addition of the 
TM interventions did not reduce tumour response rate (Table 2, Fig Supp 2c). This result was 
consistent with Chen et al 2016 [46]. From the safety perspective, none of the studies reported 
serious adverse events associated with the addition of the TM intervention to oxaliplatin 
regimens. Also, the sensitivity analyses based on ingredients did not identify any plants or 
plant combinations that significantly increased the incidence of CIN in the test groups relative 
to the controls. 
4.1. Limitations of the study 
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The 32 included studies were small in size with an average of 36 participants in the test 
groups and 33 in the control groups. Although, participants did not use chemotherapy in the 
month prior to the studies, it is likely that a proportion had been previously treated but 
separate results were not provided for these sub-groups so was not possible to determine the 
impact of this factor on CIN incidence.  
All studies reported the use of randomization but only40.6% reported a valid method for 
sequence generation and only Kono et al 2013 [37], which was the only study to use external 
trial management, reported allocation concealment. The issue of how participants were 
screened for inclusion was not addressed in any of the study reports (Table Supp 3). Therefore 
there is a risk that selection and randomization were not conducted properly so investigator 
bias could have affected the results.  
Only one study reported blinding of participants. Blinding is difficult to achieve in cancer 
trials [10] and is especially problematic when oral TM decoctions are used since these have a 
distinctive smell and taste so it is difficult to construct an identical placebo as control. 
Consequently, the participants would be well aware they were receiving a TM intervention in 
addition to other medications. Only Kono et al 2013 [37] provided a protocol, so selective 
outcome reporting could have been an issue in the other studies. The Funnel plots suggest that 
non-significant results for CIN were under-reported in small studies and it is likely that this 
has inflated the benefit identified in the meta-analysis. The paucity of reporting of the details 
of the trial methodology and consequent high risk of bias in these trials is somewhat mitigated 
for CIN since this is usually assessed independently by pathologists in Chinese hospitals and 
included in the patient record. Also, CIN was only one of multiple outcomes of the studies. 
Nevertheless, bias is an issue in this group of studies so the meta-analysis results should be 
interpreted with reservation. 
4.2. Effects of the five selected plants in experimental models 
TM interventions are usually composed of multiple ingredients with the intent of enhancing 
the effectiveness of the treatment and reducing unwanted effects [53]. Although the 
interventions varied from study to study, the same plants were used in multiple studies. This 
similarity between interventions was used as the basis for subgroup sensitivity analyses aimed 
at determining which of the plants may be contributing to reported reductions in CIN 
incidence. The multi-level analysis procedure provided a systematic approach to pooling the 
most similar TM interventions and assessing the relative clinical efficacy of different 
combinations of plants. In the selection of plants for further research, we adopted a 
conservative approach and only considered plants and groups of plants that consistently 
appeared at multiple levels in the analysis, as well as demonstrated pooled RRs that were 
significant, without heterogeneity, and were equal or better than the result for the total pool. 
Based on these criteria, these plants and groups of plants were considered likely to have 
contributed to the reduction in neutropenia incidence when combined with oxaliplatin.  
When Atractylodes, Poria, Coix, Astragalus and Codonopsis were included in a TM 
intervention, singly or various combinations, the incidence of CIN in the treatment groups 
showed greater reductions than found in the pool of 22 studies of oral TMs. Moreover, in the 
studies that used all five of these plants orally, the incidence of CIN was lower in the test 
groups (28.0% all grades; 5.2% grade 3/4) than in the controls (58.9% all grades; 14.3%grade 
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3/4) and there was zero heterogeneity in these pools. Based on these analyses it appears that 
this group of plants showed the best available clinical evidence for CIN reduction when 
combined with oxaliplatin regimens (without G-CSF) for CRC. There were insufficient data 
to assess the effects of any of these plants when combined with G-CSF.  
Significant reductions in neutropenia incidence were also found for other plants and plant 
combinations but the data were insufficient for a consistent pattern of results to be apparent. 
For example, Panax notoginseng, Ligusticum chuanxiong, Angelica sinensis and Glycyrrhiza 
uralensis all appeared in subgroups that showed the greatest reductions in CIN incidence at 
one level. However, these subgroups always included Astragalus, Atractylodes, Codonopsis, 
Poria and/or Coix. Nevertheless, it is possible that these plants also contributed to the results, 
so these plants could also be considered for further research. Some have already received 
research attention. In particular, the combination of Astragalus and Angelica is frequently 
used for neutropenia in clinical practice and has been the subject of animal studies [54,55]. 
Also, Astragalus, Atractylodes, Codonopsis, Poria, Angelica and Glycyrrhiza are all 
commonly used in China for the treatment of myelosuppression induced by chemotherapy for 
various cancers [56]. 
To explore the question of how the five main plants might reduce CIN incidence, PubMed 
and CNKI were searched for experimental studies in models of myelosuppression induced by 
cytotoxic drugs or irradiation, haematopoiesis, and immune-regulation. 
 
In murine models of myelosuppression induced by cyclophosphamide, intraperitoneal 
injections of extracts of Astragalus membranaceus injection (AMI) have been reported to 
promote colony-forming unit-fibroblast (CFU-F) formation that was associated with 
improved production of interleukin 6 and Granulocyte-macrophage colony-stimulating factor 
(GM-CSF) by bone marrow stromal cells (BMSC), increasing Bcl-2 protein and mRNA 
expression in BMSC, thus enhancing survival of BMSC and proliferation of CFU-F [57]. Oral 
administration of an extract of Astragalus root increased counts of leucocytes and bone 
marrow CD34+ cells, mean number of CD20 immunopositive B lymphocytes, and produced 
significant decreases in the mean area of fat in bone marrow sections [58]. A study of the 
hematopoietic effect of Astragalus polysaccharides (APS) on healthy human marrow in vitro 
found that compared to negative control (APS 0mg/L), APS significantly promoted colony-
forming unit granulo-monocyte formation at 5 mg/L with or without presence of GM-CSF, 
and improved the formation of colony-forming unit erythrocytes with erythropoietin. At 125 
mg/L, APS promoted erythroid burst-forming units only in combination with erythropoietin 
or phytohemagglutinin [59]. 
 
Studies of Shenqifuzheng injection, which is comprised of bioactive components of 
Astragalus and Codonopsis that mainly contain calycosin-7-O-β-glucoside, lobetyolin, and 
astragaloside IV, have reported increases in peripheral white blood cell and bone marrow cell 
counts, enhanced T cell and B cell proliferation responses, enhanced splenic natural killer cell 
activity and peritoneal macrophage phagocytosis, and restoration of the level of interleukin-2 
in the serum [60,61]. 
 
A TM called Liujunzitang which contains Codonopsis, Atractylodes, Poria and Glycyrrhiza, 
was found to increase counts of white blood cells, reticulocytes and nucleated bone marrow 
cells in mice with leukopenia induced by cyclophosphamide [62]. In a similar model, the TM 
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Shenbaiyin, which mainly is composed of Astragalus and Coix, produced a similar result [63]. 
In mice administered the microtubule inhibitor epothilone B, the co-administration of the TM 
Sijunzitang, which contains Atractylodes, Poria and Glycyrrhiza, improved immunity and 
attenuated myelosuppression [64]. 
 
In irradiation induced myelosuppression in mice, Sijunzitang was administered 7 days before 
irradiation, and continuously for 7 days after the irradiation. The SJZ showed a protective 
effect on peripheral blood counts of white cells and platelets compared to negative controls 
[65]. In mice subjected to irradiation, intragastric administration of the saponin astragaloside 
IV attenuated radiation-induced apoptosis of bone marrow cells, indicating a radio-protective 
effect [66]. When irradiated mice were injected with an extract of Astragalus root and 
Angelica sinensis root with weekly assessments for 21 days, the treatment group showed 
significant recovery of blood cells (platelets, WBC, RBC), and in the colony growth and 
histology of bone marrow cells harvested after 21 days, compared to the controls [67]. A 
multi-plant formula that contained Codonopsis was reported to promote the recovery of bone 
marrow haematopoietic function in a myelosuppression model in irradiated mice [68].  
 
A number of studies have investigated the effects of these five plants on immune response. In 
healthy chickens, Astragalus polysaccharides (APS)were injected for seven days and the 
phagocytosis rate and phagocytic index of neutrophil granulocytes in peripheral blood were 
measured for 56 days. The results showed both measures increased significantly in the APS 
group, reached the highest level at 28 days, then slowly decreased. At 56 days, the 
phagocytosis rate and phagocytic index were still higher than the negative control for APS 
doses of 12.5mg/ml, 25 mg/ml and 50 mg/ml. [69]. A study of the effects of an aqueous 
extract of APS reported the extract stimulated activity of RAW264.7 macrophages [70]. A 
polysaccharide derived from Codonopsis was reported to reduce tumor growth and activate 
the immune system in mice inoculated with Hepatoma-22 (H22) cells [71]. Codonopsis 
polysaccharides have also been reported to improve immunity in mice with 
immunosuppression induced by cyclophosphamide [72,73]. Polysaccharides from 
Atractylodes exhibited immune-enhancing activity in-vitro in a study of splenic T-lymphocyte 
proliferation [74]. A glycoprotein purified from Poria was reported to activate RAW 264.7 
macrophages in-vitro[75] and a review of the pharmacological properties of Poria found that 
its polysaccharides appear to potentiate immune response by up-regulating immune 
stimulators and down-regulating immune suppressors [76].  
 
Coix has been developed into an anti-tumor drug in China called Kanglaite injection which 
can be combined with chemotherapy. Besides its inhibitory effects on tumor growth, it has 
been reported to stimulate T cell proliferation in C57BL/6 mice with Lewis lung carcinoma 
[77], rescue the levels of CD4+ T cells in tumor bearing mice, and increase the number of T 
cells and natural killer cells in the blood of hepatocellular carcinoma patients [78].  
 
Although there have been studies of these five plants or their constituents in experimental 
models, this does not mean that these plants acted via the same mechanisms in the clinical 
studies. Also, it cannot be inferred that the plants for which there was more experimental 
evidence were more effective than other short-listed plants. These issues require further 
research. It should be noted that the sensitivity analysis procedure used for the selection of the 
above five plants did not allow any tests between the groups of TMs included in Table 3, so 
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relative ranking is not an index of clinical effectiveness. The purpose of the ranking was 
shortlisting candidates for further research from amongst a large list of potentially interesting 
TMs. 
 
4.3. Is there any evidence for synergetic effects? 
The plant combinations identified as potentially having synergistic effects in the above 
sensitivity analyses were various combinations of Codonopsis, Atractylodes, Poria, 
Astragalus and Coix. Of these, Codonopsis, Atractylodes and Poria are the main components 
of the multi-component TM Sijunzitang [79]. Sijunzitang and its modifications, which 
frequently include addition of Astragalus, have been used clinically as adjuncts to 
chemotherapy for various cancers in China [80-82]. We could not locate any studies that 
investigated potential synergistic effects of the components of Sijunzitang in models of 
neutropenia but there have been reports in other models. In AHH-1 human lymphoblasts, the 
addition of aqueous extracts of Sijunzitang improved survival and growth following 
irradiation, with an effect that was greater than for extracts of any of the four component 
plants used singly [65]. A study of normal rat small intestine epithelial IEC-6 cells, which 
aimed to investigate the effects of the individual ingredients of Sijunzitang plus Astragalus on 
promoting healing of small intestine epithelial IEC-6 cells, reported that the combination of 
Codonopsis plus Atractylodes and the combination of Atractylodes plus Astragalus, showed 
enhanced effects when compared to these TMs used singly [83].  
 
A study of rat bone marrow stem cells investigated the effects of extracts of Astragalus and 
Angelica sinensis, singly and in combination, on proliferation and vascular endothelial growth 
factor (VEGF) expression. It reported that the Astragalus promoted stem cell proliferation and 
induced protein expression of VEGF while there was no significant effect for the Angelica 
extract, however, the combination of Astragalus plus Angelica was better than Astragalus 
extract alone [84]. In a study of TMs used for neutropenia in cancer treatment in China, 
Astragalus and Angelica were the two most frequent [56]. However, the frequency of 
Angelica was relatively low in the included studies so it was not possible to determine 
whether it was consistently associated with reductions in CIN incidence.  
 
Overall, the evidence for potential synergistic effects of these TM combinations is scanty and 
the effects on neutropenia have received relatively little research attention. However, an in-
vivo study of a different combination of four TMs found marked differences in tumour 
response, body weight and/or mortality in a CRC model when certain TMs were omitted from 
the formulation [103]. Future studies could consider a similar approach to investigating the 
effects of specific TM combinations in CIN models. 
 
5. Conclusions 
These meta-analyses suggest that the addition of certain TMs to oxaliplatin regimens was 
associated with reduced CIN incidence. However, there was considerable risk that bias in the 
conduct of the studies could have influenced results so strong conclusions could not be drawn. 
Future clinical studies require adequate protocols, sufficient durations and sample sizes, and 
should report results for each grade of CIN and for neutrophil counts.  
 
Of the plants used in the clinical studies, Astragalus, Codonopsis, Atractylodes, Poria and 
Coix in various combinations were associated with reduced neutropenia incidence in multiple 
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studies when administered orally. In experimental studies, each of these plants has been 
reported to reduce myelosuppression and/or enhance immune response. However, these 
experimental studies employed a diversity of cell-lines and animal models, the test materials 
ranged from whole plant extracts to isolated compounds, and there was little evidence of 
replication. Future studies could investigate the effects of fractionated extracts of these TMs, 
singly and in combination to systematically assess their effects on neutrophil counts in animal 
models of chemotherapy and in models with intact bone marrow and immunity. This may 
lead to the development of interventions to supplement the conventional treatment of CRC. 
 
 
6. Acknowledgements 
(deleted) 
 
7. Funding support 
(deleted) 
 
8. Conflict of interest statement 
 
MS CROH-D-15-00208R1 
The authors have received no honoraria and have no financial interests or other conflicts of 
interest related to the material in this manuscript.  
 
9. Authors’ contributions 
MC, BM, IZ conducted searches, extracted and analyzed data. CX, AX, BM and MC were 
involved in the conceptualization of the study. MC and BM drafted the original version of the 
manuscript. AZ, CX, DT and IZ provided critical comment and participated in manuscript 
revisions. All authors approved the final version. 
 
 
Funding support 
1. The project is partially supported by an International Research Grant from the Guangdong 
Provincial Academy of Chinese Medical Sciences, Guangdong Province, China.  
2. Menghua Chen is supported by an Australian Postgraduate Award at RMIT University, 
Australia. 
 
Authors’ contributions 
MC, BM, IZ conducted searches, extracted and analyzed data. CX, AX, BM and MC were 
involved in the conceptualization of the study. MC and BM drafted the original version of the 
manuscript. AZ, CX, DT and IZ provided critical comment and participated in manuscript 
revisions. All authors approved the final version. 
 
Acknowledgements 
We wish to thank Dr Johannah Shergis for conducting Egger’s test.  
 
 
19 
 
 
 
10. References 
[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: 
Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359-
386. DOI:10.1002/ijc.29210. 
[2] Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action 
and antineoplastic activity. Semin in Oncol. 1998; 25:4-12. 
[3] Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic 
chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015; 14:1-
10.DOI: 10.1016/j.clcc.2014.11.002. 
[4] Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer 
Manag Res.2011; 3:79-89. DOI: 10.2147/cmr.s11250. 
[5] Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. 
Drugs. 2002; 62 Suppl 1:1-15. 
[6] Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, 
consequences, and new directions for its management. Cancer. 2004; 100:228-237. DOI: 
10.1002/cncr.11882. 
[7] Koini F, Nintos G, Georgoulias V, et al. Therapeutic strategies for chemotherapy-induced 
neutropenia in patients with solid tumors. Expert Opinion on Pharmacotherapy. 2015; 
16:1505-1519. DOI: org/10.1517/14656566.2015.1055248. 
[8] Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile 
neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care 
Cancer. 2010; 18:529-541. DOI: 10.1007/s00520-010-0816-y. 
[9] Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced 
neutropenia. The oncologist. 2005; 10: 427-437. DOI: 10.1634/theoncologist.10-6-427. 
[10] Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed 
for the treatment of advanced colorectal cancer: systematic review and economic evaluation. 
Health Technol Assess. 2008; 12:3-9, 11-162. 
[11] Sugihara K, Ohtsu A, Shimada Y, et al. Safety analysis of FOLFOX4 treatment in 
colorectal cancer patients: a comparison between two Asian studies and four western studies. 
Clin Colorectal Cancer. 2012; 11:127-137. DOI: 10.1016/j.clcc.2011.09.001. 
[12] Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line 
chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation 
of Cancer Centers. J Clin Oncol. 1998; 16:2739-2744. 
20 
 
[13] de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without 
oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18:2938-
2947. 
[14] Boisdron-Celle M, Craipeau MC, Brienza S, et al. Influence of oxaliplatin on 5-
fluorouracil plasma clearance and clinical consequences. Cancer Chem Pharm. 2002; 49:235-
243. DOI: 10.1007/s00280-001-0406-2.[15] Saarinen UM, Hovi L, Riikonen P, et al. 
Recombinant human granulocyte-macrophage colony-stimulating factor in children with 
chemotherapy-induced neutropenia. Med Pediatr Oncol. 1992; 20:489-96. 
[16] Lydaki E, Bolonaki E, Stiakaki E, Dimitriou H, Kalmantis T, Kalmanti M. Efficacy of 
recombinant human granulocyte colony-stimulating factor and recombinant human 
granulocyte macrophage colony-stimulating factor in neutropenic children with malignancies. 
Pediatr Hematol Oncol. 1995; 12:551-558. 
[17] Gomez Raposo C, Pinto Marin A, Gonzalez Baron M. Colony-stimulating factors: 
clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia. 
Clin Transl Oncol. 2006; 8:729-734. 
[18] Hecht JR, Pillai M, Gollard R, et al. A randomized, placebo-controlled phase II study 
evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal 
cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 
2010; 9:95-101. DOI: 10.3816/CCC.2010.n.013. 
[19] Hendler D, Rizel S, Yerushalmi R, et al. Different schedules of granulocyte growth 
factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a 
prospective nonrandomized study. Am J Clin Oncol. 2011; 34:619-624. DOI: 
10.1097/COC.0b013e3181f94716. 
[20] Gascón P, Tesch H, Verpoort K, et al. Clinical experience with Zarzio® in Europe: what 
have we learned? Support Care Cancer. 2013; 21:2925-2932. DOI: 10.1007/s00520-013-
1911-7 2013 
[21] Saif M, Lansigan F, Ruta S, et al. Phase I study of the botanical formulation PHY906 
with capecitabine in advanced pancreatic and other gastrointestinal malignancies. 
Phytomedicine. 2010; 17:161-169. DOI: 10.1016/j.phymed.2009.12.016. 
[22] Chen S, Flower A, Ritchie A, et al. Oral Chinese herbal medicine (CHM) as an adjuvant 
treatment during chemotherapy for non-small cell lung cancer: A systematic review. Lung 
Cancer. 2009; 68:137-145. DOI: 10.1016/j.lungcan.2009.11.008. 
[23] Chen MH, May BH, Zhou IW, et al. Integrative medicine for relief of nausea and 
vomiting in the treatment of colorectal cancer using oxaliplatin-based chemotherapy: A 
systematic review and meta-analysis. Phytother Res. 2016; Feb 23 [Epub ahead of print]. DOI: 
10.1002/ptr.5586. 
 
[24] McCulloch M, See C, Shu XJ, et al. Astragalus-based Chinese herbs and platinum-based 
chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J 
Clin Oncol. 2006; 24:419-430. DOI: 10.1200/JCO.2005.03.6392 
21 
 
[25] Chen M, May BH, Zhou IW, Xue CC, Zhang AL. FOLFOX 4 combined with herbal 
medicine for advanced colorectal cancer: a systematic review. Phytother Res. 2014; 28:976-
991. DOI: 10.1002/ptr.5092. 
[26] Gong T. Progress in Chinese medicine treatment of leucopenia after chemotherapy. [in 
Chinese]. Guiding J of Traditional Chinese Medicine and Pharmacy. 2010; 16:105-106. 
[27] Shergis JL, Zhang AL, Zhou WY, Xue CC. Panax ginseng in randomised controlled 
trials: a systematic review. Phytother Res. 2013; 27:949-965. DOI: 10.1002/ptr.4832. 
[28] Yang S, Wang LM, Wang SQ, Guo XL, Ren DM. Job's tears components and bioactivity. 
[in Chinese]. J Chinese Medicinal Materials. 2011; 34:1306-1312. 
[29] Fu J, Wang Z, Huang L, et al. Review of the botanical characteristics, phytochemistry, 
and pharmacology of Astragalus membranaceus (huangqi). Phytother Res. 2014; 28:1275-
1283. DOI: 10.1002/ptr.5188. 
[30] Moher D, Liberati A, Tetzlaff J, et al. The PRISMA Group. Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses: The PRISMA Statement. 2009; PLoS Med 6: 
e1000097. DOI:10.1371/journal.pmed1000097. 
[31] Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses 
maintains analytic consistency and incorporates all available data. BMC Med Res Methodol. 
2007; 7:1-6. DOI: 10.1186/1471-2288-7-5. 
[32] Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0. The Cochrane Collaboration. 2011: www.cochrane-handbook.org. 
[33] Deng D, Shen X. Clinical observation of Yiqixiaoji decoction combined with 
chemotherapy treatment on 18 cases of advanced colorectal cancer. [in Chinese]. Fujian J 
Traditional Chinese Medicine. 2010; 41:13-14. 
[34] Fang MZ, Li M. The curative effect of the treatment for metastatic colorectal cancer by 
the FOLFOX4 scheme combining Javanica oil emulsion and the observation of adverse 
effects. [in Chinese]. Chinese J Information on Traditional Chinese Medicine. 2008; 15:74-75. 
[35] Xu YX, Wang SL. Clinical observation of Jiangniling combined with chemotherapy 
treatment on advanced colorectal cancer. [in Chinese].China Medical Herald. 2010; 7: 84–85. 
 
[36] Zeng C, Deng XM, Du JY,et al. Clinical observation of combined traditional Chinese 
and western medicine treatment of 61 patients with advanced colon cancer. [in Chinese]. 
Chinese J Experimental Traditional Medical Formulae. 2013; 8: 335-37. 
[37] Kono T, Hata T, Morita S, et al. Goshajinkigan oxaliplatin neurotoxicity evaluation 
(GONE): a phase 2, multicenter, randomized, double blind, placebo controlled trial of 
goshajinkigan to prevent oxaliplatin induced neuropathy. Cancer Chemotherapy and 
Pharmacology. 2013; 72:1283-1290.DOI: 10.1007/s00280-013-2306-7. 
[38] Wang YT. Xiaoaipin combined with XELOX on treatment of advanced colorectal cancer 
[in Chinese]. Northern Pharmacy. 2013; 10:55. 
22 
 
[39] Li YJ, Chen JZ, Huang WX, Li XF. Treatment of Wenshen Jianpi Fang combination 
with chemotherapy for advanced colorectal cancer. [in Chinese]. Fujian J Traditional Chinese 
Medicine. 2007; 38:13-14. 
[40] Zhang Q, Wang X, Yang G. Clinical research of Guben Xiaoliu Capsule combined with 
FOLFOX4 plan for treatment of advanced colorectal cancer. [in Chinese]. Beijing J of TCM. 
2010; 14:255-257. 
[41] Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. 
Cancer. 1981; 47:207-214. 
[42] National Cancer Institute. Common Toxicity Criteria. Version 2.0. National Cancer 
Institute; 1999. 
[43] Cassidy J, Clarke S,Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus 
oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for 
metastatic colorectal cancer. J Clin Oncol. 2008; 26: 2006-12. DOI: 
10.1200/jco.2007.14.9898 
[44] Park YS, Ji JF, Zalcberg JR, et al. Oxaliplatin/5-fluorouracil-based adjuvant 
chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the 
ACCElox registry. Asia-Pacific Journal of Clinical Oncology. 2015; 11: 334–342. DOI: 
10.1111/ajco.12409. 
[45] Gascón P, Aapro M, Ludwig H, et al. Treatment patterns and outcomes in the 
prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the 
MONITOR-GCSF study). Support Care Cancer. 2016; 24:911–925. DOI: 10.1007/s00520-
015-2861-z. 
[46] Chen MH, May BH, Zhu IW, et al. Meta-analysis of oxaliplatin-based chemotherapy 
combined with traditional medicines for colorectal cancer: contributions of specific plants to 
tumor response. Integr Cancer Ther. 2016; 15:40-59. DOI: 10.1177/1534735415596424 
[47] Ding X, Xiao XY, Yang XY, et al. Clinical observation of compound Kushen injection 
combined with FOLFOX4 regime for patients with advanced colorectal cancer. [in Chinese]. 
China Oncology. 2010; 20:860-863. 
[48] Tao CL, Xu JF. Co-Kushen injection combined with chemotherapy on treatment of 
advanced colorectal cancer. [in Chinese]. Guiding J of Traditional Chinese Medicine and 
Pharmacy. 2013; 19:42-44. 
[49] Li H, Dong L, Fu S, et al. Comparative study on treatment of advanced colorectal cancer 
by Aidi injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone. [in 
Chinese]. Chinese J of Integrated Traditional and Western Medicine. 2007; 27:1086-1089. 
[50] Wang YT, Peng L. Clinical study on Aidi injection combined with FOLFOX4 regimen in 
the treatment of advanced colorectal cancer. [in Chinese]. Qingdao Med J. 2012; 44:173-
174.doi:10.2969/j.issn.1006-557 
23 
 
[51] Qiu ZC. Kang'ai Injection combined with chemotherapy in treating advanced colorectal 
cancer. [in Chinese]. Shaanxi J Traditional Chinese Medicine. 2011; 32:3-4. 
[52] Yang YF. The comparative study of Kang'ai injection combined with FOLFOX4 
regimen for advanced colorectal cancer. [thesis in Chinese]. Fuzhou, Fujian University of 
Traditional Chinese Medicine. 2008. 
[53] Jia W, Gao WY, Yan YQ, et al. The rediscovery of ancient Chinese herbal formulas. 
Phytother Res. 2004; 18:681-686. DOI: 10.1002/ptr.1506. 
[54] Yang L, Zhang LH, Yi Z. Influence of Danggui buxue tang on the proliferation of bone 
marrow cells of mice. [in Chinese]. J Clinical Rehabilitative Tissue Engineering Research. 
2007; 3:538- 539. 
[55] Yan SC, Zhu BD, Han YG, et al. Effect of different Danggui Buxue Tang combination 
and compatibility on myelosuppression in mice. [in Chinese]. Chin Pharm J. 2008; 43:1386-
1390. 
[56] Wang M, Jin J, Zhang LP, et al. Study of medication principle about Chinese medicine in 
treatment of bone marrow suppression after chemotherapy. [in Chinese]. J Liaoning 
University of TCM. 2014; 16:147-149. 
[57] Zhu XL, Zhu BD. Mechanisms by which Astragalus membranaceus injection regulates 
hematopoiesis in myelosuppressed mice. Phytother Res. 2007; 21:663-667. DOI: 
10.1002/ptr.2144. 
[58] Ismail ZM, Amin NM, Yacoub MF, et al. Myelo-enhancement by astragalus 
membranaceus in male albino rats with chemotherapy myelo-suppression.histological and 
immunohistochemical study. Int J Stem Cells. 2014; 7:12-22. DOI: 10.15283/ijsc.2014.7.1.12. 
[59] Zhang ZP, Hong JM. Study of Astragalus polysaccharides on the proliferation of human 
hematopoietic progenitor cells in vitro. [in Chinese]. Pharmacology and Clinics of Chinese 
Materia Medica. 2000; 16:16-17. DOI :10.13412/j .cnki .zyy l .2000.01.009. 
[60] Wang J, Tong X, Li P, et al. Immuno-enhancement effects of Shenqi Fuzheng injection 
on cyclophosphamide-induced immunosuppression in Balb/c mice. J Ethnopharmacol. 2012; 
139:788-795. DOI: 10.1016/j.jep.2011.12.019. 
[61] Wang J, Tong X, Li P, et al. Bioactive components on immuno-enhancement effects in 
the traditional Chinese medicine Shenqi Fuzheng Injection based on relevance analysis 
between chemical HPLC fingerprints and in vivo biological effects. J Ethnopharmacol. 2014; 
155:405-415.DOI: 10.1016/j.jep.2014.05.038. 
[62] Yuan XH. Effects of traditional LiuJunZi decoction on immunity and hematopoietic 
function of leukopenia animal model in mice. [in Chinese]. China Medical Herald. 2008; 
5:65-66. 
[63] Li YS, Jiang JL, Li T, et al. Effects of traditional Sheng Bai Yin on immune and 
hematopoietic function of leukopenia animal model in mice. [in Chinese]. J Hubei Institute 
for Nationalities (Medical Edition). 2006; 23:7-10. 
24 
 
[64] Zhang HY. Si Jun Zi Tang extracts mitigate epothilone B chemotherapeutic toxicity and 
composition analysis [thesis in Chinese]. University of Zhongnan. 2014. 
[65] Li C, Shao S, Tu XM, et al. Effects of Si Jun Zi decoction on body weight and peripheral 
blood in 60Co ϒ irradiated mice. [in Chinese]. Radiation Protection. 2015; 35:345-350. 
[66] Li YR, Cao W, Guo J, et al. Comparative investigations on the protective effects of 
Rhodioside, Ciwujianoside-B and Astragaloside IV on radiation injuries of the hematopoietic 
system in mice. Phytother Res. 2011; 25:644-653. DOI: 10.1002/ptr.3313. 
[67] Yang M, Chan GC, Deng R, et al. An herbal decoction of Radix Astragali and Radix 
Angelicae Sinensis promotes hematopoiesis and thrombopoiesis. J Ethnopharmacol. 2009; 
124:87-97. DOI: 10.1016/j.jep. 2009.04.007. 
[68] Liu M, Tan H, Zhang X, et al. Hematopoietic effects and mechanisms of Fufang Ejiao 
Jiang on radiotherapy and chemotherapy-induced myelosuppressed mice. J Ethnopharmacol. 
2014; 152:575-584. DOI: 10.1016/j.jep.2014.02.012. 
[69] Li XY, Jin LY. Effects of polysaccharide extracted from traditional Chinese medical 
herbs on the phagocytosis of neutrophil granulocyte in peripheral blood of chickens. Journal 
of Traditional Chinese Veterinary Medicine. 2014; 1:56-59. DOI:10.13823/j.cnki.jtcvm. 
2014.01.013 
[70] Zhao LH, Ma ZX, Zhu J, et al. Characterization of polysaccharide from Astragalus Radix 
as the macrophage stimulator. Cell Immunol. 2011; 271:329-334. DOI: 10.1016/j.cellimm. 
2011.07.011. 
[71] Xu C, Liu Y, Yuan G, et al. The contribution of side chains to antitumor activity of a 
polysaccharide from Codonopsis pilosula. Int J Biol Macromol. 2012; 50:891-894. DOI: 
10.1016/j.ijbiomac. 2012.01.013. 
[72] Zhang XJ, Zhu CC, Hu L, et al. Pharmacological action of polysaccharides from Radix 
Codonopsis on immune function and hematopoiesis in mice. [in Chinese]. Traditional 
Chinese Drug Research and Clinical Pharmacology. 2003, 14:174-176. 
[73] Gong QH, Zhao W, Yu L, et al. Comparison of polysaccharides from Radix Codonopsis 
in two different places of production on immune function in mice. [in Chinese]. ACTA 
Academiae Medicinae Zunyi. 2012; 35:267-270. 
[74] Sun W, Meng K, Qi C, et al. Immune-enhancing activity of polysaccharides isolated 
from Atractylodis macrocephalae Koidz. Carbohydr Polym. 2015; 126:91-96. DOI: 
10.1016/j.carbpol. 2015.03.034. 
[75] Chang HH, Yeh CH, Sheu F. A novel immunomodulatory protein from Poria cocos 
induces Tolllike receptor 4-dependent activation within mouse peritoneal macrophages. J. 
Agric Food Chem. 2009; 57:6129-6139. DOI: 10.1021/jf9011399. 
[76] Rios JL. Chemical constituents and pharmacological properties of Poria cocos. Planta 
Med. 2011; 77:681-91. DOI: 10.1055/s-0030-1270823. 
25 
 
[77] Pan P, Wu Y, Guo ZY et al. Antitumor activity and immunomodulatory effects of the 
intraperitoneal administration of Kanglaite in vivo in Lewis lung carcinoma. J 
Ethnopharmacol. 2012; 143:680-5. DOI: 10.1016/j.jep.2012.07.025. 
[78] Huang X, Qin J, Lu S. Kanglaite stimulates anticancer immune responses and inhibits 
HepG2 cell transplantation induced tumor growth. Mol Med Rep. 2014; 10:2153-2159. DOI: 
10.3892/mmr.2014.2479. 
[79] Duan SH, Peng B, Yang RX. Analysis of application of prescription Sijunzitang. [in 
Chinese]. J Practical Traditional Chinese Internal Medicine. 2011; 25:84-85. 
[80] Huang ZH. Sijunzitang combined conventional radiotherapy for esophageal cancer 
randomized parallel group study. [in Chinese]. J Practical Traditional Chinese Internal 
Medicine. 2014; 28:74-76. 
[81] Zhang D, Chen Q, Mo JP. Sijunzitang combined treatment of lung cancer chemotherapy 
Azasetron gastrointestinal reactions: randomized controlled study. [in Chinese]. J Practical 
Traditional Chinese Internal Medicine. 2013; 27:121-123. 
[82] Gan YL, Jiao D, Liu WF. Treatment of gastrointestinal cancer multi-drug resistance 
gene-positive cases by Sijunzitang with chemotherapy. [in Chinese]. Chinese J Experimental 
Traditional Medical Formulae. 2010; 16:253-255. 
[83] Zhang ZL, Chen WW. The influence of the combination of codonopsis, astragalus, and 
atractylodes on the proliferation of small intestine epithelial IEC-6 cells. [in Chinese]. J 
Guangzhou University of Traditional Chinese Medicine. 2002; 19:137-140. 
[84] Shen B, Chen L, Zhou K, Jin KK. Effects of astragalus and angelica on bone marrow 
stem cells proliferation and VEGF protein expression in vitro. [in Chinese]. China J Orthop 
Trauma. 2011; 24:652-655. 
[85] Hu A, Chuan Y, Li Z. The Clinical efficacy of chemotherapy combined with Chinese 
traditional drugs for advanced colorectal cancer patients. [in Chinese]. The Practical J Cancer. 
2006; 21:74-76. 
[86] Lao GQ, Chen F, He XH, et al. Clinical research on treating advanced colorectal cancer 
with the Jianpi Jiedu decoction plus chemotherapy. [in Chinese]. Clinical J Chinese Medicine. 
2012; 4:1- 3. 
[87] Lim MH, Zhu DZ. Pien Tze Huang combined with chemotherapy on treatment of 
advanced colon cancer. [in Chinese]. Fujian J Traditional Chinese Medicine. 2012; 43:8-9. 
[88] Liu H, Sun MF. Clinical observation of kang'ai fangyi tablet combined with 
chemotherapy in treating advanced colorectal cancer. [in Chinese]. Chinese J Information on 
Traditional Chinese Medicine. 2009; 16:2. 
[89] Liu J, Wang W, Zhou Y. Observation on therapeutic effect of Jianpi Huoxue herbs 
combined with chemotherapy in treating post-operational colonic cancer patients. [in 
Chinese]. Chinese J Integr Med. 2005; 25:207-209. 
26 
 
[90] Liu WY, Liu QY, Liu HW et al. Clinical study of combination of Chinese traditional and 
Western medicine for 16 advanced colorectal cancer. [in Chinese]. Jilin J Traditional Chinese 
Medicine. 2011; 31:984-985. 
[91] Ma J, Wang G, Cai D, Fan Y, Gu X. Clinical observation of Jianpi Xiaoliu decoction in 
preventing post-operative colorectal carcinoma recurrence and metastasis. [in Chinese]. 
Shanghai J TCM. 2005; 39:24-25. 
[92] Song WX, Zhang WW. Clinical study of combination of Xiaoliuhuaji Decoction II and 
chemotherapy on the treatment of advanced colorectal cancer. [in Chinese]. Jiangxi J of TCM. 
2012; 44:13-14. 
[93] Wang H. The observation on efficacy of Yiqi Huoxue Buchang decoction with 
chemotherapy in patients with rectal cancer of post-operation. [in Chinese]. J of Liaoning 
University of TCM. 2008; 10:81-82. 
[94] Wang JZ, Ke YH, Liu PC, Wu CY, Chen HB. Yichangning decoction combined with 
FOLFOX4 on treatment of advanced colorectal cancer. [in Chinese]. Fujian J TCM. 2011; 
42:23-24. 
[95] Wu G, Yu G, Li J, Xiong F. Short term therapeutic effect on treatment of post-
operational large intestine carcinoma by Fupiyiwei decoction combined with chemotherapy 
and it's effect on immune function. [in Chinese]. China J Chinese Materia Medica. 2010; 
35:782-785. 
[96] Yang CB, Yuan J, Zhu L. Clinical study on jianpikangfu pills for treatment of 50 cases of 
advanced colorectal cancer. [in Chinese]. J Emerg TCM. 2007; 16:1198-1199. 
[97] Zeng J, Li Z, Wang X. Traditional Chinese medicine with chemotherapy treatment on 
advanced colorectal carcinoma: reported of 30 cases. [in Chinese]. J Jiangxi University of 
Traditional Chinese Medicine. 2008; 20:39-41. 
[98] Zhang Q, Zhao W, Yu J, Wang X. Clinical study on advanced colorectal cancer treated 
by Yiqi Huoxue TCM combined with chemotherapy. [in Chinese]. Chinese J Information on 
TCM. 2006; 13:17-18. 
[99] Zhang WW, Song WX. Clinical study of combination of Xiaoliuhuaji decoction I and 
chemotherapy on the treatment of post-operative colorectal cancer. [in Chinese]. Hebei J 
TCM. 2013; 35:69-71. 
[100] Zhang Y, Xu J, Sun J. Clinical study of Jianpi Jiedu decoction plus FOLFOX4 regimen 
in the treatment of advanced colorectal cancer. [in Chinese]. Global Traditional Chinese 
Medicine. 2010; 3:117-120. 
[101] Zhou J. Observation of clinical efficacy of Fuzheng Jianpi decoction combined with 
chemotherapy in treatment of advanced colorectal cancer. [in Chinese]. Chinese Archives of 
TCM. 2011; 29:2814-2816. 
27 
 
[102] Zeng DX, Ling Y, Yang QL, Sun Y. Ginsenoside Rg3 capsules combined with 
FOLFOX4 regimen for treatment of advanced colon cancer: a report of 35 cases. [in Chinese]. 
J Bengbu Medical College 2009; 34: 1092-94. 
[103] Liu SH, Chang YC. Old formula, new Rx: The journey of PHY906 as cancer adjuvant 
therapy. J Ethnopham. 2012; 140: 614-623. DOI:10.1016/j.jep.2012.01.047. 
28 
 
11. Biographies 
Menghua Chen graduated with a Bachelor of Medicine (BMed) from Guangzhou University 
of TCM, China in 1985. He worked as a physician in the Guangdong Hospital of TCM until 
1990. Since 1991 he has been in private practice in Melbourne, Australia and is currently a 
doctoral candidate at RMIT University where he is undertaking clinical and experimental 
research into natural products for colorectal cancer.  
Brian H May received a Master of Letters from University of New England, Australia in 
1997 and a PhD from RMIT University in 2010. He is currently a research fellow at RMIT 
University and has authored over 40 peer reviewed articles in the fields of natural products, 
clinical trials, systematic reviews and meta-analysis.  
Iris Wenyu Zhou received a PhD from RMIT University, Australia in 2008. She has worked 
as a research fellow at RMIT University for 6 years. Her current research expertise and 
interests include health workforce, educational research, population surveys on the utilisation 
of complementary and alternative medicine, questionnaire and survey design, critical 
appraisal of clinical evidence, systematic reviews and meta-analysis.  
Daniel Man-yuen Sze obtained his PhD in Immunology (University of Birmingham UK) and 
a second PhD in Higher Education (University of Sydney Australia). As a cancer 
Immunologist, Daniel was awarded an Australian NSW Cancer Institute Career Development 
Fellowship and established the ‘Cancer Immunology Group’ at the Faculty of Pharmacy of 
the University of Sydney. He led the cancer research theme under the National Institute of 
Complementary Medicine (Australia) NICM Collaborative Centre of Traditional Chinese 
Medicine and is Secretary General of the Advisory Committee of the Consortium for 
Globalisation of Chinese Medicine. 
Charlie C Xue is Head of School, School of Health Sciences, RMIT University. He 
graduated from Guangzhou University of Chinese Medicine, China in 1987 as Graduate of the 
Year and received a PhD from RMIT University in 2000. He is a member of the World Health 
Organization (WHO) Expert Advisory Panel for Traditional Medicine; Director of the World 
Health Organization (WHO) Collaborating Centre for Traditional Medicine; and Chair of the 
national regulatory authority the Chinese Medicine Board of Australia. He has been a 
principal investigator on more than 20 research projects including project grants from the 
National Health and Medical Research Council (NHMRC), Australian Research Council 
(ARC) and other projects funded by industry and government. These and other research 
endeavors have resulted in over 200 publications and 25 PhD graduates. 
Tony Zhang is Head of Discipline of Chinese Medicine at the School of Health Sciences, 
RMIT University, Australia and Deputy Director of China-Australia International Research 
Centre for Chinese Medicine. He has a Bachelor of Medicine (Chinese Medicine) from China, 
a Master of Public Health from the University of New South Wales and PhD from RMIT 
University. His research expertise is in systematic review/meta-analysis and the management 
of multi-centre clinical trials. He has published more than 60 peer-reviewed journal articles, 
book chapters and research reports. He is internationally active in contributing to professional 
activities including: External Reviewer for Australian National Health and Medical Research 
Council Project Grant and Hong Kong Health and Medical Research Fund; Editorial Board 
Member of 10 scientific journals including American Journal of Chinese Medicine and BMC 
29 
 
Complementary and Alternative Medicine. He has been a reviewer for 25 scientific journals 
including Cochrane Database Systematic Review; PLOS One; British Journal of Cancer; 
American Journal of Public Health; Pharmacoepidemiology & Drug Safety and Phytotherapy 
Research. 
 
  
30 
 
12. Figure captions 
 
Fig. 1. Flow diagram of the search and selection process of RCTs of oxaliplatin regimens 
combined with traditional medicine (TM) for colorectal cancer (CRC) with chemotherapy 
induced neutropenia (CIN) as an outcome 
Legend 
CT: clinical trial of TM without randomisation; DU: duplicate publication; MT: multi-cancer CT; RE: 
review; Other: not a controlled trial, not a CT of TM; G-CSF: Granulocyte colony-stimulating factor. 
 
Fig. 2. Grade 3/4 CIN incidence by number of cycles of oxaliplatin based chemotherapy 
t: test groups; c: control groups 
  
Fig 1. 
Records identified from English 
language databases 
(n=1,019) 
S
cr
ee
n
in
g
 
In
cl
u
d
ed
 
E
li
g
ib
il
it
y
 
Id
en
ti
fi
ca
ti
o
n
 
Records identified from Chinese 
language databases 
CNKI & CQVIP (n=1,575) 
2,163 records after duplicates 
removed 
2,163 records screened based on 
titles & abstracts 
Not a clinical study of 
CRC in humans 
(n=1,883) 
280 full-text articles assessed for 
eligibility 
Excluded based on full 
text (n=168) 
[CT n=64, DU n=13, MT 
n=40, RE n=8, Other n=67] 
88 studies of chemotherapy + 
TM for CRC 
Records identified through searches of 
reference lists and print journals (n=54) 
Not Oxaliplatin regimen 
(n=9);  
No outcome for CIN (n=39); 
Reported myelosuppression only 
(n=6); 
Data not suitable for meta-
analysis (n=2). 
32 studies reporting data on CIN 
included in meta-analysis 
Figure
Fig. 2. 
4.14 4.19 
2.55 
5.13 
10.28 
12.3 
6.92 
11.28 
12.75 
19 
0 
5 
10 
15 
20 
25 
30 
2 3 4 6 >/=8 
C
IN
 i
n
ci
d
en
ce
 %
 (
m
ea
n
 ±
S
E
) 
No. of cycles of chemotherapy 
t % 
c % 
Figure
31 
 
Table 1: Characteristics of randomised controlled trials of traditional medicines (TM) 
combined with oxaliplatin-based regimens for colorectal cancer (CRC) with CIN 
incidence as an outcome 
Firs
t 
aut
hor 
(yea
r). 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
TNM (T/C); 
KPS/ ECOG  
TM Intervention; 
dosage & duration 
Oxaliplatin regimen; dose, 
cycles (T/C) 
Outcom
e: CIN 
gr.: T/C 
Den
g D 
(201
0)33. 
18/18; 9/9; 
54.17±10.04/5
3.56±11.10. 
IV (all); KPS 
≥60. 
Yiqixiaoji decoction; 
one decoction per day, 
for up to 6 wks. 
XELOX: Ox. 130 mg/m², 2hours 
ID, day 1; Xel. 850 mg/ m², bid, 
for 14 days; 21 days/cycle, for 2 
cycles; G-CSF used. 
I: 2/4;II: 
1/1; 
III: 
0/1;IV: 
0/0. 
Din
g X 
(201
0)46. 
30/30; 18/20; 
64.5/63 (med.) 
ACRC (all); 
KPS ≥70 
Co-Kushen injection; 
20 ml, ID, day 1-7, 14 
day/cycle, for 8 
cycles. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 8/8 cycles. 
I: 
9/10;II: 
3/6; 
III: 
0/1;IV: 
0/0. 
Fan
g M 
(200
8)34.  
48/45; 30/28; 
59.5 ± 
11.3/56.4 ± 
10.3 
IV(all); KPS 
≥70. 
Javanica oil emulsion 
injection; 30 ml, ID, 
day 1-14 / cycles, for 
two cycles 
FOLFOX 4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2. 2/2 cycles; G-CSF used. 
I/II: 
19/17; 
III/IV: 
2/1. 
Hu 
A 
(200
6)84. 
28/22; 18/14; 
49.3±4.5/48.5
±4.3 
IV (all); KPS 
≥50. 
Treatment with 4 
different TM 
decoctions according 
to symptom 
differentiation; one 
decoction per day, for 
more than 30 days. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 200mg /m², ID, day 1-
2, 5-FU 2400mg /m², ID, 46 
hours, cycle/21 days, 2/2 cycles. 
I: 4/7;II: 
2/6; 
III: 
0/1;IV: 
0/0. 
Kon
o T 
(201
3)37. 
44/45; 23/25; 
67/61 (med) 
NS; ECOG 0–
1 
TJ-107 Goshajinkigan 
aqueous extracts; or 
placebo was 
administered orally, 
tid, before each meal 
(7.5 g/day) for 26 wks 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2 or mFOLFOX6: Ox.85 
mg/m², ID, day 1, LV 200mg 
/m², ID, 5-FU 400 mg bolus, 
follow 2400 mg /m², ID for 46 
hours, 14 days/cycle, 8/8 cycles 
or more. 
All gr.: 
15/21; 
≥
III:10/15. 
Lao 
G 
(201
2)85. 
30/30; 21/23; 
35.1±20.2/36.
7±20.1. 
II:5/7, III: 
15/14, 
IV:10/9; KPS 
≥60 
Jianpijiedu decoction; 
one decoction per day, 
21 days /cycle, for two 
cycles. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 200mg /m², ID, day 1, 
5-FU 500 mg bolus day 1, 
2400mg /m², ID, 48 hours, day 1-
2, 21 days /cycle, 2/2 cycles. 
I: 4/9;II: 
3/5; 
III: 
1/4;IV: 
0/0. 
Li H 
(200
7)48. 
65/52; 43/36; 
58/59 (med.) 
III: 27/19, 
IV:38/33; 
KPS ≥60 
Aidi injection; 60ml, 
ID, day 1-10, 14 
days/cycle, for 11wks. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 5.5/5.5 cycles (mean). 
I: 
9/14;II: 
5/7; 
III: 
3/5;IV: 
0/1. 
Li Y 
(200
7)39.  
20/18; 22 
(all); 72.2 
(med. all) 
III: 15, IV: 23 
(all); KPS ≥
60 
Wenshenjianpi 
decoction; one 
decoction per day, for 
10-12 wks. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 6/5.5 cycles (med.). 
I: 
5/10;II: 
4/4; 
III: 
1/1;IV: 
0/0. 
Lim 
M 
(201
2)86. 
24/23; 17/14; 
56.89±14.77/5
5.37±16.01 
III: 15/16, IV: 
9/7; KPS 
84.78±14.66/
83.42±13.09 
Pianzaihuang capsule; 
two capsules, bid; 14 
days/cycle, 8-10 
cycles. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
I: 5/7;II: 
1/4; 
III: 
0/1;IV: 
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day1-2, 8-10/8-10 cycles. 0/0. 
Liu 
H 
(200
9)87. 
36/34; 16/18; 
50.2 (med. all) 
ACRC (all); 
KPS ≥60 
Kang’ai fangyi pian; 
one decoction per day, 
21 days / cycle, for 3 
cycles. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 200mg /m², ID, day 1-
5, 5-FU 300 mg /m², ID, day 1-5, 
21 days / cycle, 3/3 cycles.  
I: 7/9;II: 
2/5; 
III: 
1/1;IV: 
0/0. 
Liu 
J(20
05)8
8. 
43/21; 23/10; 
61.52 ±10.12 
/60.11 ±9.78 
IV (all); KPS 
≥50. 
Jianpihuoxue 
formulae; one 
decoction per day, 30 
days/ cycle, 3 cycles. 
FOLFOX: Ox.150 mg/m², ID, 
day 1, LV 200mg /m², ID, day 1-
5, 5-FU 500 mg /m², ID, day 1-5, 
30 days/ cycle, 3/3 cycles. 
I: 5/5;II: 
2/3; 
III: 
1/1;IV: 
0/0. 
Liu 
W 
(201
1)89. 
16/16; 11/10; 
51/52(mean) 
IV (all); KPS 
40-60(range). 
Yierkang capsule; 4-6 
capsules, bid, for 5-25 
months. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 100mg /m², ID, day 1-
5, 5-FU 400 mg /m², ID, day 1-5, 
21 days / cycle, 6 /6 cycles. 
All gr.: 
3/12. 
Ma 
J 
(200
5)90. 
28/25; 15/13; 
58.1/57.5(mea
n) 
II:7/4,  
III: 
21/21;KPS ≥
60. 
Jianpi Xiaoliu 
decoction; one 
decoction per day, 90 
days/ cycle, 2 cycles. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 200mg /m², ID, day 1-
5, 5-FU 375 mg /m², ID, day 1-5, 
21 days / cycle, 6/6 cycles. 
I: 4/8;II: 
2/2; 
III: 
0/0;IV: 
0/0. 
Qiu 
Z 
(201
1)50. 
22/21; 14/13; 
56.9/52.7(med
.) 
IV (all);KPS 
≥60. 
Kang’ai injection; 40 
ml, ID, day 1–10, 14 
days/ cycle, for 4 
cycles. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 21 days /cycle, 4/4 
cycles. 
III/IV: 
1/8. 
Son
g W 
(201
2)91. 
20/20; 12/13; 
56.4±9.1 
/48.3±8.2 
ACRC (all); 
KPS ≥70. 
Xiaoliuhuajichangfan
g II; one decoction per 
day, 21 days/ cycle, 2 
cycles. 
FOLFOX: Ox.135 mg/m², ID, 
day 1, LV 200mg /m², ID, day 1-
2, 5-FU 2400 mg /m², ID, for 48 
hours, 21 days/ cycle, 2 /2 cycles. 
I: 2/4;II: 
3/3; 
III: 
1/2;IV: 
0/1. 
Tao 
C 
(201
3)47. 
74/74; 51/50; 
60.1+7.9 
/60.4+8.9. 
ACRC (all); 
KPS 
65.6+12.3/66.
7+14.5 
Co-kushen injection; 
15 ml per day, 
ID,started 14 days 
before chemotherapy, 
5wks/cycle, for 3 
cycle. 
FOLFOX: Ox.135 mg/m², ID, 
day 1, LV 200mg/m², ID, 2 
hours, day 1-5, 5-FU 
500mg/m² ,ID, 8-10 hours, day1-
5, 3wks/cycle, 3/3 cycle. 
I: 
10/14;II: 
5/16; 
III: 
5/5;IV: 
0/0. 
Wan
g H 
(200
8)92. 
34/34; 20/22; 
52.58±8.12/51
.11±7.72 
IV:34/34; 
KPS ≥50. 
Yiqiguoxiebuchang 
decoction; one 
decoction per day, for 
3 mths.  
FOLFOX: Ox.85 mg/m², ID, day 
1, LV 200mg/m², ID, day 1-2, 5-
FU 500 mg bolus day 1, 5-FU 
2500 mg/m², ID, for 48 hours, 21 
days/ cycle, 4/4 cycles. 
I: 4/8;II: 
2/5; 
III: 
1/2;IV: 
0/0. 
Wan
g J 
(201
1)93. 
30/30; 18/21; 
52.3±6.2/ 
56.7±7.8. 
ACRC (all); 
KPS ≥60. 
Yichangning 
decoction; one 
decoction per day, for 
2 mths. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 21 days /cycle, 2/2 
cycles. 
I/II: 
8/14; 
III/IV: 
1/5. 
Wan
g Y 
(201
2)49. 
38/36; 26/25; 
52(med. all). 
ACRC (all); 
KPS ≥70. 
Aidi injection; 80 ml, 
ID, per day, 
10days/cycle,for 4 
cycles. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 4/4 cycles. 
All gr.: 
21/28. 
Wan
g Y 
(201
3)38. 
32/30; 20/19; 
NS. 
ACRC (all); 
KPS ≥70. 
Xiaoaiping injection; 
60ml, ID, per day, 14 
days/ cycle, for two 
cycles. 
XELOX: no details, 2/2 cycles. All gr.: 
20/26. 
 
Wu 
G(2
010)
94. 
33/25; 23/17; 
55.4 ±13.6 
/52.8 ±15.2. 
I: 5/3, II:10/8, 
III: 15/11, 
IV:3/3; KPS 
≥60. 
Fupiyiwei decoction; 
one decoction per day, 
for 24 wks. 
FOLFOX 4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 12/12 cycles. 
I: 7/8;II: 
2/6; 
III: 
1/3;IV: 
0/0. 
Xu 
Y 
(201
61/60; 38/37; 
53/52(mean, 
all) 
ACRC (all); 
≥70 
Jiangniling formula; 
one decoction per day, 
14 days/cycle, for 8-
FOLFOX 4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
5.03±2.1
4/3.03±1
.27(mean
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0)35.  10 cycles bolus, 600mg /m², ID, 22 hours, 
day1-2, 11.1/7.8 (mean) cycles. 
) 
Yan
g C 
(200
7)95. 
50/50; 29/27; 
51.36±10.58 
/53.48±9.35. 
ACRC (all); 
KPS ≥60. 
Jianpikangfu pill; 6g, 
tid, for 4 wks. 
FOLFOX: Ox.135 mg/m², ID, 
day 1, LV 100mg /m², ID, day 1-
5, 5-FU 425 mg /m², ID day 1-5, 
4/4 wks. 
I: 
18/18;II: 
6/14; 
III: 
0/3;IV: 
0/0. 
Yan
g Y 
(200
8)51. 
30/30; 16/19; 
51.07+10.44 
/51.33+10.95. 
ACRC (all); 
KPS ≥60. 
Kang'ai injection; 50 
ml, ID, day1-20, 
30days/cycle, for 2 
cycles. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 4/4 cycles. 
I: 
9/11;II: 
2/8; 
III: 
1/3;IV: 
0/0. 
Zen
g C 
(201
3)36.  
61/30; 
39/19; 54. 3 
±6. 3/53. 2 ± 
6. 6 
III: 20/12 
IV:41/18; 
KPS ≥60. 
Fuzhengxiaoji 
decoction; one 
decoction per day, 14 
days/cycle, for 4 
cycles. 
FOLFOX: Ox.85 mg/m², ID, day 
1, LV 200mg /m², ID, day 1-2, 5-
FU 360-500 mg /m² bolus, 600 
mg /m², ID, for 22 hours, day 1-
2, 14 days/cycle, 4/4 cycles. 
4.56±1.3
3/3.27±1
.08(mean
) 
Zen
g D 
(200
9)101
. 
35/32; 25/21; 
50<: 4/5, 51-
69:28/25, >70:
3/2. 
IV (all); KPS 
≥70. 
Ginsenoside Rg3 
capsules: 2 capsules, 
bid, for 8 wks. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 21 days /cycle, 4/4 
cycles. 
All gr.: 
22/28. 
Zen
g J 
(200
8)96. 
30/30; 19/18; 
48/60 (med.). 
ACRC (all); 
KPS ≥60. 
Multi-TM formulae; 
one decoction per day, 
for 4wks. 
FOLFOX 4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 2/2 cycles. 
I: 
12/16;II: 
7/8; 
III: 
1/2;IV: 
0/1. 
Zha
ng 
Q 
(200
6)97. 
38/30; 35(all); 
54.8(mean 
all). 
ACRC (all); 
KPS:76.5±5.8
/73.5±6.0 
Yiqihuoxue formulae; 
one decoction per day, 
21 days/ cycle, for 3 
cycles. 
FOLFOX: Ox.125 mg/m², ID, 
day 1, LV 200mg /m², ID, day 1-
2, 5-FU 500 mg /m² bolus, day 1-
2, 2000 mg /m² ID for 72 hours, 
21 days/cycle, 3/3 cycles. 
I: 5/9;II: 
2/4; 
III: 
1/1;IV: 
0/0. 
Zha
ng 
Q 
(201
0)40. 
60/60; 35/33; 
56.2(mean 
all);  
ACRC (all); 
KPS ≥60. 
Gubenxiaoliu capsule; 
4 capsules, bid, for 8 
wks.  
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 4/4 cycles. 
I: 
10/7;II: 
3/8; 
III: 
2/6;IV: 
0/0. 
Zha
ng 
W 
(201
3)98. 
32/32; 15/16; 
56.8±10.1/46.
4±9.2. 
II:23/22; III: 
9/10; 
KPS ≥70. 
Xiaoliuhuaji decoction 
I; one decoction per 
day, for 5 mths.  
FOLFOX: Ox.135 mg/m², ID, 
day 1, LV 200mg /m², ID, day 1-
2, 5-FU 2400 mg /m² , ID for 48 
hours, 21 days/cycle, 6/6 cycles. 
I: 6/8;II: 
4/7; 
III: 
1/4;IV: 
0/2. 
Zha
ng 
Y 
(201
0)99. 
21/20; NS; 
NS;  
ACRC (all); 
KPS≥60. 
Jianpijiedu decoction; 
one decoction per day, 
for 4 wks. 
FOLFOX 4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 400mg /m², 
bolus, 600mg /m², ID, 22 hours, 
day1-2, 2/2 cycles. 
I/II: 4/8; 
III/IV: 
1/3. 
 
Zho
u J 
(201
1)100
. 
34/34; 22/20; 
51.2/52.5. 
II: 14/13, III: 
16/11, IV:6/5; 
KPS≥60. 
Fuzhengjianpi 
decoction; one 
decoction per day, for 
8 wks. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 100mg /m², ID, day 1-
5, 5-FU 500 mg /m², ID, day 1-5, 
28 days/cycle, 2/2 cycles. 
I: 1/6;II: 
3/7; 
III: 
3/4;IV: 
0/2. 
RN: reference number (superscript), T: treatment group, C: control group, M: male, N: number, CIN: 
chemotherapy induced neutropenia, gr.: WHO recommendations for grading of acute and subacute toxicity grade, 
NS: not stated, ID: intravenous drip, TNM: cancer staging system. ‘T’ for tumor, denotes the extent of invasion of 
the intestinal wall, ‘N’ for lymphatic node, the amount of lymphatic node involvement, and ‘M’ for metastasis. 
KPS: Karnofsky Performance Status; ECOG: Eastern Cooperative Oncology Group Performance Status; TM: 
Traditional medicine. 5-FU: 5-Fluorouracil; LV: Leucovorin; Ox.: Oxaliplatin; Xel: Capecitabine; FOLFOX: Ox. 
+ 5-FU + LV; XELOX: Ox. + Capecitabine; ACRC: advanced colorectal cancer; bid: twice per day; tid: three 
times per day; qd: once per day; wk: week; mth: month; med.: median. 
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Table 2. Meta-analysis results for CIN (FN, grades 4, 3, 3/4, 1/2, all grades), Neutrophil 
count and Tumour response rate  
Group 
No. studies 
(participant 
No. T/C) 
Ref Nos. 
EoT 
(between 
groups) RE 
I2 
Incidence 
T/C(%) 
Outcome: CIN 
1. Injection group (no G-CSF): 7 studies 
Gr 4 1(65/52) 48 
0.27 [0.01, 
6.44], p = 
0.42 
NA 
T: 0% 
(0/65); 
C: 1.9% 
(1/52) 
Gr 3 4(199/186) 46-48,51 
0.62 [0.28, 
1.40], p = 
0.25 
0 
T: 4.5% 
(9/199); 
C: 7.5% 
(14/186) 
Gr3/4 5(221/207) 46-48,50,51 
0.47 [0.22, 
0.98], p = 
0.04* 
0 
T: 4.5% 
(10/221); 
C: 11.1% 
(23/207) 
Gr1/2 4(199/186 46-48, 51 
0.58 [0.44, 
0.77], p = 
0.0001* 
0 
T: 26.1% 
(52/199); 
C: 46.2% 
(86/186) 
All grades 6(269/252) 38,46-51 
0.65 [0.55, 
0.76], p < 
0.00001* 
0 
T: 37.9% 
(102/269); 
C: 61.5% 
(155/252) 
2. Oral administration group (no G-CSF): 21 studies 
FN 1(44/45) 37 
0.20 [0.01, 
4.14], p = 
0.30 
NA 
T: 0% 
(0/44); 
C: 4.4% 
(2/45) 
Gr 4 4(116/116) 91,96,98,100 
0.25 [0.05, 
1.18], p = 
0.08 
0 
T: 0% 
(0/116); 
C: 5.2% 
(6/116) 
Gr 3 15(509/462) 39,40,84,85,87,88,91,92,94-100 
0.37 [0.21, 
0.65], p = 
0.0005* 
0 
T: 3.1% 
(16/509); 
C: 9.5% 
(44/462) 
Gr3/4 17(583/537) 37,39,40,84,85,87,88,91-100 
0.44 [0.29, 
0.66], p = 
0.0001* 
0 
T: 4.6% 
(27/583); 
C: 12.5% 
(67/537) 
Gr1/2 19(635/585) 37,39,40,84-88,90-100 
0.62 [0.54, 
0.72], p < 
0.00001* 
0 
T: 25.8% 
(164/635); 
C: 44.1% 
(258/585) 
All grades 21(686/633) 37,39,40,84-101 
0.59 [0.53, 
0.67], p < 
0.00001* 
0 
T: 31.5% 
(216/686); 
C: 57.8% 
(366/633) 
Total: groups 1 and 2 (no G-CSF): 28 studies 
Gr 4 5(181/168) 48,91,96,98, 100 
0.26 [0.06, 
1.03], p = 
0.05 
0 
T: 0% 
(0/181); 
C: 4.2% 
(7/168) 
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Gr 3 19(708/647) 
39,40,46-
48,51,84,85,87,88,91,92,94-100 
0.42 [0.27, 
0.67], p = 
0.0002* 
0 
T: 3.5% 
(25/708); 
C: 9.6% 
(62/647) 
Gr3/4 22(804/743) 
37,39,40,46-
48,50,51,84,85,87,88,91-100 
0.45 [0.31, 
0.65], p < 
0.0001* 
0 
T: 4.6% 
(37/804); 
C: 11.8% 
(88/743) 
Gr1/2 23(834/771) 37,39,40,46-48,51,84-88,90-100 
0.61 [0.54, 
0.70], p < 
0.00001* 
0 
T: 25.9% 
(216/834); 
C: 43.3% 
(334/771) 
All grades 27(955/885) 37-39,40,46-49,51,84-101 
0.61 [0.56, 
0.67], p < 
0.00001* 
0 
T: 33.3% 
(318/955); 
C: 58.9% 
(521/885) 
3. G-CSF group: 2 studies 
Grade 3/4 2(66/63) 33,34 
1.00 [0.15, 
6.63], p 
=1.00 
0 
T: 3.0% 
(2/66); 
C: 3.2% 
(2/63) 
All grades 2(66/63) 33,34 
0.91 [0.48, 
1.74], p 
=0.78 
27 
T: 36.3% 
(24/66); 
C: 38.1% 
(24/63) 
4. Neutrophil count: 2 studies 
Total 
neutrophils 
(MD) 
2(122/90) 35,36 
MD: 1.62 
[0.93, 2.32], 
p < 
0.00001* 
66 NA 
Outcome: Tumour response rate (tRR)for studies included in CIN groups1 
1. Injection group (no G-CSF): 6 studies that reported CIN data for Grade 3/4 and/or all grades 
Reported 
CINGr3/4 
4(191/177) 47,48,50,51 
1.43 [1.04, 
1.96], p = 
0.03* 
37 
T: 52.4% 
(100/191); 
C: 35.0% 
(62/177) 
Reported 
CIN all 
grades 
5(239/222) 38,47,48,49,51 
1.38 [1.07, 
1.78], p = 
0.01* 
27 
T: 51.9% 
(124/239); 
C: 36.5% 
(81/222) 
2. Oral administration group(no G-CSF): 17 studies 
Reported 
CIN Gr3/4 
16(534/482) 37,39,40,84,85,87,88,91-97,99,100 
1.21 [1.03, 
1.42], p = 
0.02* 
0 
T: 40.3% 
(215/534); 
C: 33.0% 
(159/482) 
Reported 
CIN all 
grades 
17(569/514) 37,39,40,84,85,87,88,91-97,99-101 
1.20 [1.03, 
1.41], p = 
0.02* 
0 
T: 40.6% 
(231/569); 
C: 33.5% 
(172/514) 
Total for groups 1 and 2 (no G-CSF): 23 studies 
Reported 
CIN Gr3/4 
20(725/659) 
37,39,40,47,48,50,51,84,85,87,88,91-
97,99,100 
1.29 [1.13, 
1.48], p = 
0.0002* 
0 
T: 43.4% 
(315/725); 
C: 33.5% 
(221/659) 
Reported 
CIN all 
grades 
23(832/759) 37-40,47-49,51,84-88,91-97,99-101 
1.27 [1.13, 
1.44], p = 
0.0001* 
0 
T: 44.6% 
(371/832); 
C:34.9% 
(265/759) 
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3. G-CSF group: 1 study 
Reported 
CIN Grade 
3/4&all 
grades 
1(48/45) 34 
1.16 [0.77, 
1.74], 
p=0.47 
 
T: 54.2% 
(26/48); 
C:46.7% 
(21/45) 
4. Neutrophil count: 2 studies 
Did not 
report CIN 
grades 
2(122/90) 35,36 
1.24 [0.92, 
1.66], 
p=0.16 
0 
T: 52.5% 
(64/122); 
C:42.2% 
(38/90) 
T: treatment group; C control group; EoT: end of treatment; * significant at p< 0.05 
1. included studies reported both CIN data for Grade 3/4 and/or all grades plus data for tumour 
response rate.  
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Table 3: Effects of specific TMs on CIN (all grades): single TMs and combinations  
Level Traditional Medicine (TM) RR 95%CI N. stud. Refs. 
N. 
part. 
I² 
1 
Angelica sinensis(Oliv.) Diels. (dang 
gui) 
0.38 [0.22,0.64] 2[85,98] 118 0 
1 
Ligusticum chuanxiong Hort. (chuan 
xiong)  
0.38 [0.22,0.66] 2[85,89] 114 0 
1 Glycyrrhiza uralensis Fisch. (gan cao) 0.40 [0.27,0.60] 3[85,94,101] 178 0 
1 
Amomum kravanh Pierre ex. Gagnep. 
(bai dou kou) 
0.41 [0.26,0.65] 2[95,101] 126 0 
1 
Pinellia ternata (Thunb.) Breit. (ban 
xia) 
0.45 [0.31,0.64] 3[94,95,98] 186 0 
1 Smilax glabra Roxb. (tu fu ling) 0.46 [0.27,0.80] 2[91,98] 121 0 
1 Citrus reticulata Blanco (chen pi) 0.46 [0.29,0.72] 2[86,94] 120 0 
1 Eclipta prostrata L. (mo han lian) 0.47 [0.29,0.75] 2[88,101] 138 0 
1 Paeonia lactifloraalba. (bai shao) 0.47 [0.34,0.65] 4[85,92,95,99] 212 0 
1 
Sparganium stoloniferum Buch.-
Hamil. (san leng) 
0.47 [0.27,0.81] 2[89,93] 132 0 
1 
Spatholobus suberectus Dunn (ji xue 
teng) 
0.48 [0.34,0.68] 3[94,98,99] 192 0 
1 
Actinidia arguta (Sieb. & Zucc) 
Planch. ex Miq. (teng li gen) 
0.49 [0.29,0.84] 2[92,98] 108 0 
1 Smilax china L. (ba qia) 0.49 [0.30,0.81] 2[91,94] 113 0 
1 Poria cocos (Schw) Wolf (fu ling) 0.50 [0.42,0.60] 13[37,39,85,86,89,91-95,98,99,101] 780 0 
1 Ligustrum lucidum Ait. (nu zhen zi) 0.51 [0.33,0.79] 2[88,94] 130 0 
1 
Curcuma zedoaria (Berg.) Rosc. or C. 
phaeocaulis Val. (e zhu) 
0.51 [0.38,0.67] 6[88,89,91,93,94,99] 379 0 
1 
Panax notoginseng (Burk.) F.H. Chen 
(san qi) 
0.51 [0.36,0.72] 4[87,88,93,94] 245 0 
1 Lycium barbarum L. (gou qi zi) 0.52 [0.38,0.71] 3[39,88,94] 168 0 
1 
Akebia quinata (Thunb.) Decne. (ba 
yue zha) 
0.52 [0.38,0.72] 5[88,91,92,94,100] 264 0 
1 Dioscorea opposita Thunb. (shan yao) 0.52 [0.39,0.71] 4[37,85,95,99] 261 4 
1 
Curcuma wenyujin Y. H. Chen et C. 
Ling (yu jin) 
0.53 [0.36,0.79] 2[39,91] 91 0 
1 
Vitis quinquangularis Rehd. (ye pu 
tao teng) 
0.53 [0.38,0.73] 4[91,94,99,100] 218 0 
1 
Codonopsis pilosula (Franch.). Nannf. 
(dang shen) 
0.54 [0.45,0.65] 10[39,86,89,91-94,96,99,101] 615 0 
1 
Astragalus membranaceus (Fisch.) 
Bge. (huang qi) 
0.55 [0.47,0.65] 12[39,86,88-91,93,94,97,98,100,101] 682 0 
1 Coix lacryma-jobi L. (yi ren) 0.56 [0.48,0.66] 13[39,40,85,86,88,91,93-95,97,98,101] 773 0 
1 
Epimedium brevicornum 
Maxim(yinyanghuo) 
0.57 [0.43,0.77] 4[39,40,91,94] 271 0 
1 
Atractylodes macrocephala Koidz. 
(bai zhu)  
0.57 [0.50,0.66] 15[39,85,86,88,89,91-94,96-101] 962 0 
1 
Scutellaria barbataD. Don. (ban zhi 
lian) 
0.61 [0.50,0.74] 6[39,86,88,93,94,97] 356 0 
1 Hedyotis diffusa Willd. (she she cao) 0.63 [0.51,0.79] 5[86,92-94,97] 288 0 
1 Agrimonia pilosa Ledeb. (xian he cao) 0.65 [0.48,0.88] 2[88,96] 170 0 
2 Poria + Coix 0.46 [0.37,0.57] 9[39,85,86,91,93-95,98,101] 523 0 
2 Poria + Atractylodes 0.47 [0.39,0.57] 11[39,85,86,88,91-94,98,99,101] 633 0 
2 Paeonia + Poria 0.47 [0.34,0.65] 4[85,92,95,99] 212 0 
2 Vitis + Atractylodes 0.50 [0.36,0.70] 4[91,94,99,100] 218 0 
2 C. zedoaria + Atractylodes 0.51 [0.38,0.67] 6[88,89,91,93,94,99] 379 0 
2 Akebia + Atractylodes 0.52 [0.38,0.72] 5[88,91,92,94,100] 264 0 
2 Poria + Dioscorea 0.52 [0.39,0.71] 4[37,85,95,99] 261 4 
2 Codonopsis + Atractylodes 0.54 [0.45,0.65] 10[39,86,89,91-94,96,99,101] 615 0 
2 Coix + Atractylodes 0.56 [0.47,0.67] 10[39,85,86,88,91,93,94,97,98,101] 595 0 
2 Astragalus + Atractylodes 0.56 [0.48,0.67] 11[39,86,88,89,91,93,94,97,98,100,101] 650 0 
2 Epimedium + Coix 0.57 [0.43,0.77] 44[39,40,91,94] 271 0 
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2 Atractylodes + Hedyotis 0.63 [0.51,0.79] 5[86,92-94,97] 288 0 
2 Agrimonia + Atractylodes 0.65 [0.48,0.88] 2[88,96] 170 0 
3 Poria + Atractylodes + Ligusticum 0.38 [0.22,0.66] 2[85,89] 114 0 
3 Poria + Coix + Amomum 0.41 [0.26,0.65] 2[91,101] 126 0 
3 Poria + Coix + Pinellia 0.45 [0.31,0.64] 3[94,96,98] 186 0 
3 Poria + Dioscorea + Paeonia 0.45 [0.32,0.64] 3[85,90,99] 172 0 
3 Poria + Coix + Atractylodes 0.46 [0.37,0.59] 8[39,85,86,91,93,94,98,101] 465 0 
3 Poria + Astragalus + Smilax glabra 0.46 [0.27,0.80] 2[91,98] 121 0 
3 Poria + Atractylodes + Astragalus 0.47 [0.38,0.60] 8[39,86,89,91,93,94,98,101] 479 0 
3 Poria + Coix + Astragalus 0.48 [0.37,0.61] 7[39,86,91,93,94,98,92101] 415 0 
3 Spatholobus + Poria + Atractylodes 0.48 [0.34,0.68] 3[94,98,99] 192 0 
3 Poria + Atractylodes + Paeonia 0.48 [0.33,0.71] 3[85,92,99] 154 0 
3 Poria + Atractylodes + Actinidia 0.49 [0.29,0.84] 2[92,98] 108 0 
3 Poria + Atractylodes + Codonopsis 0.50 [0.40,0.62] 9[39,86,89,91-94,99,101] 515 0 
3 
Astragalus + Atractylodes + C. 
zedoarea 
0.50 [0.36,0.69] 5[88,89,91,93,94] 315 0 
3 Astragalus + Atractylodes + Akebia 0.51 [0.35,0.72] 4[88,91,94,100] 224 0 
3 Coix + Atractylodes + Astragalus 0.58 [0.48,0.69] 9[39,86,88,91,93,94,97,98,101] 545 0 
4 
Poria + Atractylodes+ Angelica + 
Coix 
0.38 [0.22,0.64] 2[85,98] 118 0 
4 
Poria + Atractylodes + Glycyrrhiza + 
Coix 
0.40 [0.27,0.60] 3[85,94,101] 178 0 
4 
Paeonia + Dioscorea + Poria+ 
Atractylodes 
0.45 [0.29,0.71] 2[86,99] 114 0 
4 
Astragalus + Atractylodes + Coix + 
Eclipta 
0.47 [0.29,0.75] 2[88,101] 138 0 
4 
Astragalus + Atractylodes + Akebia + 
Vitis 
0.48 [0.31,0.74] 3[91,94,100] 154 0 
4 
Codonopsis + Astragalus + 
Atractylodes + Poria 
0.48 [0.38,0.62] 7[39,86,89,91,93,94,101] 411 0 
4 
C. zedoaria + Poria + Atractylodes + 
Codonopsis 
0.49 [0.36,0.67] 5[89,91,93,94,99] 309 0 
4 
Poria + Codonopsis + Atractylodes + 
Hedyotis  
0.49 [0.35,0.70] 4[86,92-94] 228 0 
4 
Astragalus + Coix + C. zedoaria + 
Atractylodes 
0.51 [0.36,0.73] 4[88,91,93,94] 251 0 
4 
Codonopsis + Atractylodes + Poria + 
Akebia 
0.52 [0.34,0.80] 3[91,92,94] 153 0 
4 
Paeonia + Codonopsis + Atractylodes 
+ Poria 
0.55 [0.35,0.86] 2[92,99] 104 0 
4 
Astragalus + Coix + Atractylodes + 
Scutellaria 
0.61 [0.50,0.74] 6[39,86,88,93,94,97] 356 0 
4 
Astragalus + Atractylodes + Coix + 
Hedyotis 
0.61 [0.46,0.80] 4[86,93,94,97] 248 0 
5 
Astragalus + Atractylodes + Poria + 
Smilax glabra + Coix  
0.46 [0.27,0.80] 2[91,98] 121 0 
5 
Codonopsis + Poria + Astragalus + C. 
zedoaria + Atractylodes 
0.48 [0.33,0.70] 4[89,91,93,94] 245 0 
5 
Astragalus + Coix + Poria + 
Codonopsis + Atractylodes 0.49 [0.37,0.63] 6
[39,86,91,92,94,101] 348 0 
5 
Codonopsis + Atractylodes + Poria + 
C. zedoaria + Vitis 
0.51 [0.35,0.73] 3[91,94,99] 177 0 
5 
Atractylodes + Hedyotis + Akebia + 
Poria + Codonopsis 
0.52 [0.32,0.84] 2[92,94] 100 0 
5 
Astragalus + Coix + Atractylodes + C. 
zedoaria + Akebia 
0.52 [0.35,0.76] 3[88,91,94] 183 0 
5 
Lycium + Atractylodes + Coix + 
Astragalus + Scutellaria 
0.53 [0.39,0.73] 3[39,88,94] 168 0 
5 
Atractylodes + Astragalus + Coix + 
Hedyotis + Scutellaria 
0.61 [0.46,0.80] 4[86,93,94,97] 248 15 
6 
Codonopsis + Astragalus + Coix + 
Glycyrrhiza + Atractylodes + Poria 
0.43 [0.27,0.68] 2[94,101] 128 0 
6 
Astragalus + Coix + Poria + Pinellia + 
Spatholobus + Atractylodes 
0.45 [0.28,0.72] 2[943,98] 128 0 
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6 
Hedyotis + Scutellaria + Coix + 
Codonopsis + Astragalus + Poria 
0.47 [0.32,0.69] 3[86,93,94] 188 0 
6 
Astragalus + Atractylodes + Poria + 
Codonopsis + C. zedoaria + 
Sparganium 
0.47 [0.27,0.81] 2[89,93] 132 0 
6 
Codonopsis + Atractylodes + 
Astragalus + Coix + Poria + 
Scutellaria 
0.50 [0.37,0.68] 4[39,86,93,94] 226 0 
6 
Astragalus + Atractylodes + Poria + 
Codonopsis + Coix + C. zedoaria 
0.50 [0.33,0.75] 3[91,93,94] 181 0 
6 
Codonopsis + Atractylodes + Poria + 
C.zedoaria + Vitis + Spatholobus 
0.50 [0.33,0.75] 2[94,99] 124 0 
6 
C.zedoaria + Astragalus + 
Atractylodes + Coix + Panax + 
Scutellaria 
0.51 [0.35,0.74] 3[88,93,94] 198 0 
6 
Codonopsis + Poria + Atractylodes + 
Coix + Astragalus+ Epimedium 
0.53 [0.37,0.83] 339,91,94 152 0 
7 
Astragalus + Coix + Codonopsis + 
Poria + Atractylodes + C. wenyujin+ 
Epimedium 
0.55 [0.37,0.83] 2[39,91] 91 0 
8 
Scutellaria + Hedyotis + Codonopsis 
+ Atractylodes + Poria + Astragalus + 
Coix + Citrus 
0.46 [0.29,0.72] 2[86,94] 120 0 
8 
Codonopsis + Poria + Atractylodes + 
Coix + Astragalus + Lycium+ 
Scutellaria + Epimedium 
0.53 [0.36,0.76] 2[39,94] 98 0 
9 
Scutellaria + Hedyotis + C.zedoaria + 
Codonopsis + Atractylodes + 
Astragalus + Poria + Coix + Panax  
0.48 [0.30,0.78] 2[93,94] 128 0 
9 
Ligustrum + Panax + C. zedoaria + 
Akebia + Scutellaria + Lycium + Coix 
+ Atractylodes + Astragalus 
0.51 [0.33,0.79] 2[88,94] 130 0 
10 
Akebia + C. zedoaria + Vitis + Coix + 
Atractylodes + Astragalus + 
Codonopsis + Poria + Smilax china + 
Epimedium 
0.49 [0.30,0.81] 2[91,94] 113 0 
 
RR: risk ratio; part.: participants; CI: confidence interval; stud.: studies.  
Notes: Full botanical names are provided for level 1 with Chinese pin yin names in parentheses. Genus names are 
used for subsequent levels with abbreviated botanical name being used when clarity is required. RRs are listed in 
ascending order for each level. Lower RRs are associated with greater reductions in risk. Data with no significant 
effect or heterogeneity greater than 30% have been excluded 
 
